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ZUSAMMENFASSUNG
Unser Labor konnte zeigen, dass Sumoylierung des E2 konjugierenden Enzyms Ubc9 zur 
Diskriminierung von SUMO Substraten in Säugetieren beiträgt. Sumoyliertes Ubc9 (S*Ubc9) 
zeigt keinen Effekt bei der Modifikation der meisten SUMO Substrate, aber 
interessanterweise inhibiert es die Sumoylierung von RanGAP1 und verstärkt signifikant die 
Sumoylierung des Transkriptionsregulators Sp100 (Knipscheer et al., 2008). Sp100 war 
allerdings das einzige Substrat zu dieser Zeit, das mit dem sumoylierten Ubc9 verstärkt 
modifiziert wurde. Um Einblicke in die Substratreichweite des S*Ubc9 zu bekommen, 
wurden in vitro Sumoylierungsreaktionen mit Ubc9 und S*Ubc9 auf einem Protein 
Microarray (“ProtoArray® Human Protein Microarray v5.0”) von Invitrogen  durchgeführt. 
Über 9000 menschliche Proteine sind darauf gespottet. Protein Microarrays wurden 
entwickelt, um schnell und sensitiv neue Substrate für Phosphorylierung und Ubiquitinierung 
zu identifizieren (Gupta et al., 2007; Ptacek et al., 2005; Zhu et al., 2001). In dieser Arbeit 
wurden Protein Microarrays als neuer Ansatz zur Identifizierung von Substraten für das 
S*Ubc9 verwendet. Bevor jedoch in vitro Sumoylierungsreaktionen mit dem S*Ubc9 auf dem 
ProtoArray® durchgeführt werden konnten, wurden alle notwendigen Komponenten in E.coli 
exprimiert und aufgereinigt. Dies beinhaltete SUMO1, HA getaggtes SUMO1, das 
heterodimere E1 Enzym Aos1/Uba2, Ubc9 und S*Ubc9. Ubc9 wurde in großem Maßstab 
sumoyliert und die modifizierte wurde von der unmodifizierten Form mittels 
chromatographischer Methoden getrennt. Die Bedingungen für den ProtoArray® wurden in 
in vitro Sumoylierungsreaktionen mit bereits bekannten Substraten wie Sp100 und E2-25K 
ausgetestet. Der ProtoArray® selbst wurde vom Invitrogen ProtoArray® Service 
durchgeführt. Sie verwendeten unser Konzept und die etablierten Bedingungen für die 
Reaktion. Neu identifizierte Substrate wurden in unserem in vitro System verifiziert und
werden Einblicke in die biologische Funktion des S*Ubc9 liefern.
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ABSTRACT
Our laboratory has discovered a novel mechanism of how sumoylation of the E2 conjugating 
enzyme Ubc9 contributes to target discrimination in mammals. Whereas sumoylated Ubc9
(S*Ubc9) does not interfere with the sumoylation of most SUMO substrates, it impairs 
modification of RanGAP1 and significantly enhances modification of the transcriptional 
regulator Sp100 (Knipscheer et al., 2008). However, Sp100 was the only substrate so far
preferentially targeted by S*Ubc9. In order to get insights into the substrate range of 
S*Ubc9, in vitro sumoylation reactions with Ubc9 and S*Ubc9 were performed on a protein 
microarray chip (“ProtoArray® Human Protein Microarray v5.0”) purchasable from 
Invitrogen. Over 9000 human proteins were spotted on such a microarray. They were
developed as rapid and sensitive means to identify novel substrates for phosphorylation and 
ubiquitination (Gupta et al., 2007; Ptacek et al., 2005; Zhu et al., 2001). In this work, the 
ProtoArray® was applied for sumoylation reactions as a novel approach to identify 
substrates for S*Ubc9. Before performing the in vitro sumoylation reaction with S*Ubc9 on 
the ProtoArray®, all components were expressed and purified in E. coli. This included 
SUMO1, HA tagged SUMO1, the heterodimeric E1 enzyme, Ubc9 and S*Ubc9. Ubc9 was in 
vitro sumoylated in large scale and separated from the unmodified form by using 
chromatographic methods. Conditions for the ProtoAarray were tested in in vitro
sumoylation reactions on known SUMO substrates like Sp100 and E2-25K. The ProtoArray®
itself was performed by the Invitrogen ProtoArray® service using our concept and the 
established conditions for the reaction. Newly identified substrates were verified in our in 
vitro system and will provide novel insights in the biological function of S*Ubc9.
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1. INTRODUCTION
Post-translational modifications of proteins are an easy and rapid way to reversibly 
modulate the target’s activity, stability or localisation. The most common post-translational 
modifications are phosphorylation, acetylation, methylation, ADP-ribosylation, 
ubiquitination and sumoylation. All of them play an essential role in cellular processes 
including cell signalling, maintenance of chromatin structure, regulation of gene expression, 
stress response, ribosome biogenesis and DNA repair. Reversible modifications with 
ubiquitin and its relatives, the ubiquitin-like proteins, are needed for the dynamic control of 
cellular events and for adaption to changing environmental conditions without de novo 
protein synthesis. Some of the well-known ubiquitin-like proteins are NEDD8, the interferon-
inducible ISG15, FAT10 and the subject of this thesis, SUMO (small ubiquitin-related 
modifier) 1, 2.
1.1. The SUMO family
Figure 1: Tertiary structure of Ubiquitin (right panel) and SUMO1 (left panel) from ModBase 3
SUMO is a small protein, 10.5kD in size, which gets covalently attached to its substrates. It is 
ubiquitously expressed in all eukaryotes, but missing in eubacteria and archea. One single 
SUMO gene has been identified in yeast and invertebrates, whereas in vertebrates four 
isoforms are known: SUMO1, SUMO2, SUMO3 and SUMO4 1, 2, 4, 5. SUMO1-3 are expressed 
ubiquitously, although there are tissue specific variations 6. SUMO4 expression is restricted 
to kidney, spleen and lymph nodes 7, 8. Interestingly, the loss of SUMO1 in mice is not lethal 
and can be compensated by SUMO2/3 9. Paralog specific substrates exist, but the set of 
substrates for SUMO1 and SUMO2/3 is mostly overlapping. Between mammalian SUMO2 
and SUMO3 sequence similarity is about 95% and both share a sequence similarity with 
mammalian SUMO1 of ~50%. Notably, all 4 SUMO isoforms have only about 18% sequence 
identity with Ubiquitin, but they share a highly similar tertiary structure, as shown in Figure 
1. Due to their non-related amino acid sequence, Ubiquitin and SUMO differ in the overall 
charge. At physiological conditions, SUMO is charged negatively in contrast to Ubiquitin, 
which is charged positively. In addition, the SUMO family members possess an extended, 
N
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flexible N-terminus, which is 14 residues longer than the one of Ubiquitin (also seen in Figure 
1). SUMO is mostly conjugated to its substrate as a single moiety. SUMO2/3 chains have 
been observed, but the relevance is still unclear. Furthermore, most of the SUMO1 pool in a 
cell is conjugated to its substrates, whereas SUMO2/3 is mainly free and may build up a 
reservoir to react on specific stress signals 10.
1.2. SUMO modification cycle
Sumoylation is dependent on the equilibrium of conjugation and deconjugation. All SUMOs 
are conjugated to their substrates via an ATP-dependent enzymatic cascade closely related 
to ubiquitination. Deconjugation is achieved by a set of isopeptidases. In Figure 2 the 
conjugation and deconjugation cycle is shown schematically.
Figure 2: Sumoylation cycle
All SUMO members first need to be processed to free their Gly-Gly motif. SUMO is then activated in an ATP-dependent 
manner by forming a thioester with the E1 enzyme. Subsequently, SUMO is transferred to the E2 again resulting in a 
thioester bond. In the final step, SUMO is transferred with or without the help of an E3 ligating enzyme to the target lysine 
in the substrate resulting in an isopeptide bond. SUMO specific isopeptidases are able to reverse SUMO conjugation.
The enzymatic cascade responsible for SUMO conjugation involves an activating E1 enzyme, 
a conjugating E2 enzyme and usually, but not mandatory, a ligating E3 enzyme. SUMO’s E1, 
E2 and E3 are specific for sumoylation and not able to substitute ubiquitin specific enzymes. 
SUMO is expressed as a precursor, which needs to be cleaved by SUMO specific proteases
prior to target attachment. Upon processing, the C-terminal Gly-Gly motif is freed, which is a 
prerequisite for conjugation. The E1 enzyme then promotes the activation of SUMO in an 
ATP-dependent manner. All eukaryotic organisms contain only one single SUMO-activating 
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enzyme, a heterodimer between Aos1 and Uba2. For activation a thioester bond is 
transiently formed between the C terminal glycine of SUMO and the catalytic cysteine C173 
of the E1 subunit Uba2 11, 12. In the next step of conjugation SUMO is transferred to the sole 
E2 conjugating enzyme Ubc9. The catalytic cysteine C93 of Ubc9 forms again a thioester 
bond with the C-terminal glycine of SUMO, which is then ready to get conjugated to its 
substrate. Upon SUMO conjugation, the substrate linkage is formed as an isopeptide bond 
between the C-terminal glycine of SUMO and the target lysine. In some cases Ubc9 itself is 
sufficient for conjugation 13, but there are several SUMO substrates depending on E3 ligase 
activity for efficient modification. E3 ligases accelerate the SUMO transfer from the E2 
enzyme to the substrate and usually ensure substrate specificity. Most E3 ligases interact 
with both the SUMO loaded Ubc9 and the substrate, bring them in close vicinity and thereby 
push the SUMO transfer from the E2 enzyme to the substrate 14. This mechanism is best 
understood for the Siz/Pias E3 ligase family, which possess a SP-RING finger - a domain 
related to the RING finger of ubiquitin E3 ligases. Other SUMO E3 ligases, like RanBP2,
accelerate sumoylation by optimal positioning of the SUMO loaded E2 to the substrate for 
efficient transfer 15, 16. In order to guarantee the reversibility of sumoylation, SUMO specific 
proteases, also known as isopeptidases, are able to cleave the isopeptide bond between 
SUMO and its substrate. In humans six SUMO specific proteases (Senp1-3 and Senp5-7) have 
been described for deconjugation, all of which belong to the family of ubiquitin-like 
proteases (Ulp). They share a C-terminal 200 amino acid core domain, which contains the 
catalytic triad (Cys-His-Asn), whereas their N-terminal regions are different. Besides SUMO
isopeptide bond cleavage, they are responsible for SUMO processing and SUMO chain 
editing 17, 18. 
1.3. SUMO consensus motif
The target lysine, where SUMO is covalently linked to, is often located in a SUMO consensus 
?????????????????????????????????????????????????????????????????????????This motif is directly 
contacted by Ubc9. The target lysine reaches into the catalytic pocket of Ubc9 and the 
aliphatic and acidic amino acids interact with the residues on the surface of Ubc9 19.  
However, the SUMO consensus motif can only be recognized by Ubc9 when present in an 
extended loop structure or an unstructured area 20. Two variants of the SUMO consensus 
motif have been identified: a phosphorylation dependent SUMO motif (PDSM) and a 
negatively charged one (NDSM). The PDSM contains a phosphorylated serine and proline in 
direct neighbourhood to the classical SUMO consensu???????????????????? 21. The NDSM is 
defined due to its acidic amino acids in addition to the SUMO consensus motif 22. 
1.4. Non-covalent SUMO interaction
Besides covalent attachment, SUMO can also non-covalently interact with its substrates via a 
SUMO interaction motif (SIM) or a SUMO binding motif (SBM) in the interaction partners. 
This motif consists of a ?-strand that can bind to SUMO???2-strand due to the environment 
of the hydrophobic core. The SIM core unit is defined as V/IxV/IV/I/L 23, 24, 25, 26. SUMO-SIM 
INTRODUCTION
4
binding can occur in both, parallel and anti-parallel, orientation 27. The general motif is 
further determined for SUMO1 binding by a stretch of acidic amino acids and/or
phosphorylated serine residues in the neighbourhood imposing a negative charge. 
Phosphorylation as well as negatively charged acidic amino acids modulate the specificity 
and orientation of SIM binding to SUMO1 28. In contrast to SUMO1, SUMO2-SIM binding is
not dependent on acidic amino acids and phosphorylation 26. Mainly, the core SUMO2-SIM 
interaction is enough for a stable non-covalent interaction. Overall, the SUMO-SIM 
recognition is much more specific than the recognition of ubiquitin binding domains by 
ubiquitin, NEDD8 or FAT10 26.
1.5. Consequences of sumoylation
Although often only a small fraction of a certain protein is sumoylated at a given time, the 
consequences for the respective protein can be determining. They can range from altered 
intracellular localization to changes in activity or stability. In general, it is assumed that 
SUMO changes interactions and can either interfere with an existing binding interface 
between substrate and a binding partner or provide a new one via SIM interaction 20, 29 . 
Moreover, sumoylation has also been revealed to cause conformational changes by 
intramolecular SIM binding 30. Among the best studied functions SUMO plays an essential 
role in DNA repair and genomic integrity 30, 31, 32 protein stability 33, 34, 35 nuclear-cytosolic
transport 36, 37, 38 and transcriptional regulation 39, 40, 41 .
1.6. The sole SUMO conjugating enzyme Ubc9
The 18kD Ubc9 is the sole E2 conjugating enzyme for sumoylation. As already mentioned, it 
possesses two essential functions in the SUMO conjugation pathway: accepting the activated 
SUMO from the E1 enzyme Aos1/Uba2, thereby forming a thioester linkage, and 
subsequently transferring SUMO to the lysine of its target. Because of its central role in this 
enzymatic cascade, it requires a binding interface for the E1 and E3 enzymes. Notably, a 
patch surrounding the active cysteine C93 of Ubc9 binds directly to the consensus sequence 
in the substrate. This interaction is not efficient for the transfer of SUMO to the target lysine, 
but sufficient for some substrates. Like for Aos1 and Uba2, Ubc9 is essential in all eukaryotic 
organisms tested except S. pombe 42. The expression levels of Ubc9 differ between organs 
and tissues 43. Interestingly, Ubc9 expression is frequently upregulated in human cancer 44. 
To date less is known about the molecular mechanisms regulating the expression of such a 
central enzyme in sumoylation. But there is evidence for the regulation of Ubc9 on the post-
translational level. For example during oxidative stress, low H2O2 concentrations induce 
reversible disulfide bond formation between the catalytic cysteines of the Uba2 E1 subunit 
and Ubc9. The result is a loss of SUMO conjugation and consequently, desumoylation of 
most cellular SUMO targets 45. Moreover, Ubc9 was shown to be modified by S-nitrosylation 
upon treatment with the nitric oxide donor GSNO 46.
Intriguingly, another post-translational modification of Ubc9 is its own sumoylation outlined 
in 1.7. in more detail.
INTRODUCTION
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1.7. Sumoylation of Ubc9
Sumoylated Ubc9 (S*Ubc9) has been identified in every screen for novel SUMO substrates 25, 
47, 48, 49. Sumoylation of the mammalian Ubc9 has then been mapped to lysine K14 in a non-
consensus SUMO acceptor site in vivo and in vitro 29. The structurally similar ubiquitin E2 
conjugating enzyme E2-25K is also sumoylated at lysine K14 in a non-consensus site in its N-
terminus. But despite these structural similarities, sumoylation of Ubc9 does not impair its 
enzymatic activity as shown for E2-25K 20. However, our laboratory has recently shown that 
sumoylation of Ubc9 regulates target discrimination in mammals. Sumoylated Ubc9 
strikingly enhances the modification of the transcriptional regulator Sp100 comparable to E3 
ligases. Sp100 contains a SIM, which is able to interact with SUMO linked to lysine K14 of 
Ubc9. This additional binding interface increases the affinity between Sp100 and the 
sumoylated Ubc9, thus resulting in enhanced modification. On the other hand, other 
substrates are not affected by sumoylated Ubc9 or even impaired. For example, sumoylation 
of Ubc9 has no effect on E2-25K modification but impairs activity on RanGAP1. These 
findings suggest a role for Ubc9 contributing to target recognition and possibly controlling 
sumoylation in an E3 ligase independent way 29.
1.8. Controlling SUMO conjugation
In contrast to the large number of SUMO substrates, only a few SUMO E3 ligases are known 
and it is currently unclear, how substrate specificity is performed. One mechanism to ensure 
substrate specificity is by controlling substrates and enzymes in a spatial and temporal 
manner. Another explanation is that several E3 ligases await identification. Intriguingly,
recent studies point to a central role of Ubc9 in target selection 19, 29.
In our working model, we propose that the affinity between SUMO loaded Ubc9 and the 
substrate determines the modification efficiency. In the classical way, an increase in affinity 
is achieved via E3 ligases, which bind both the E2 and the substrate and bring them in close 
proximity for an efficient SUMO transfer (Figure 3, E3 dependent). Recent studies have 
revealed different mechanism of how substrate affinity can be increased in an E3 
independent manner. The best understood example is RanGAP1, which stably interacts with 
Ubc9 via an additional binding interface next to the interaction with the SUMO consensus 
site in the substrate. This additional interface is required for efficient modification (Figure 3, 
E3 independent, left pannel) 19. Alternatively, thioester (Figure 3, E3 independent, middle 
panel) or isopeptide (Figure 3, E3 independent, middle panel) bonded SUMO to Ubc9 can 
increase the affinity to the substrate. This depends on a functional SIM motif in the 
substrate. To date substrates like Daxx 30, TDG 50, USP25 51, BLM and HIPK2 52 were described 
to depend on a functional SIM for efficient sumoylation, which enhances the affinity for 
SUMO loaded Ubc9. For the sumoylated Ubc9 currently only Sp100 was identified as 
substrate 29.
INTRODUCTION
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Figure 3: Model of E3 dependent and independent target recognition in SUMO conjugation (adapted from Knipscheer et 
al., 2008)29
Ubc9 is shown in yellow, SUMO in green, RING type E3 ligase in pink. Ubc9´s catalytic cleft directly binds to SUMO 
consensus motifs ???xE/D). This interaction is not sufficient for an efficient SUMO transfer from Ubc9 to the target. RING 
E3 ligases bind to both, the substrate and Ubc9, and stabilise the interaction for efficient SUMO transfer (E3 dependent). An
increase in substrate/Ubc9 affinity can also be achieved by E3 independent mechanism via additional binding interfaces 
(grey) with either Ubc9 (E3 independent, left panel), the SUMO~Ubc9 thioester (E3 independent, middle panel) or the 
SUMO modified Ubc9 (E3 independent, right panel). Interaction via SUMO bound to Ubc9 depends on a SIM in the target.
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2. AIM OF THIS WORK
Our laboratory has discovered a novel mechanism of how sumoylation of Ubc9 contributes 
to target discrimination. Whereas sumoylated Ubc9 does not interfere with the sumoylation 
of most SUMO substrates, it impairs modification of RanGAP1 and significantly enhances 
modification of the transcriptional regulator Sp100 29. To date Sp100 is the sole substrate for 
this mechanism and the aim of this thesis was the identification of additional substrates 
targeted by S*Ubc9. In order to address this aim, in vitro sumoylation reactions with Ubc9 
and S*Ubc9 were performed on a protein microarray chip (“ProtoArray® Human Protein 
Microarray v5.0”) purchasable from Invitrogen. Such microarrays contain over 9000 human 
proteins and were developed as rapid and sensitive means to identify novel substrates for 
phosphorylation and ubiquitination 53, 54, 55. In this study the ProtoArray® was applied for
sumoylation reaction. The advantage of this particular array is that proteins were expressed 
in insect cells as N-terminal GST fusions using a baculovirus expression system. Purification 
was under native conditions to preserve protein structure. The proteins were printed in 
duplicates at a reported level on the ProtoArray®, which guarantees reliable and 
reproducible results 56. To perform an in vitro sumoylation reaction with S*Ubc9 on this
ProtoArray®, all components needed to be expressed and purified in an E. coli expression 
system. This included the SUMO1, HA tagged SUMO1, the E1 enzyme and Ubc9. To obtain 
S*Ubc9, Ubc9 was in vitro sumoylated and separated from the unmodified form. Conditions 
for the ProtoAarray were established in in vitro sumoylation reactions on known SUMO
substrates. The ProtoArray® itself was performed by the Invitrogen ProtoArray® service 
using our established conditions for the reaction. Newly identified substrates were verified 
in our in vitro system and will provide novel insights in the biological function of S*Ubc9. 
RESULTS
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3. RESULTS
3.1. Purification of recombinant proteins
For producing high amounts of modified Ubc9, all components for the sumoylation reaction 
were expressed in E. coli and purified to near homogeneity. This included the purification of 
SUMO1, the heterodimeric E1 enzyme Aos1/Uba2 and the E2 enzyme Ubc9.
3.1.1. Large scale purification of recombinant SUMO1
SUMO1 cloned under the control of the T7 promoter was transformed into the bacterial 
E.coli strain BL21 gold and expression was induced by addition of IPTG in a total of 4 litres 
culture. In the first purification step, the negatively charged SUMO1 was bound to Q 
Sepharose (GE Healthcare), a strong anion exchange matrix. The retained SUMO1 was 
subsequently eluted with Tris-HCl buffer, pH 7.5, containing high salt. In the final step the 
SUMO1 containing fractions were applied to a HiLoad S200 size exclusion chromatography 
column on a FPLC (Fast protein liquid chromatography) Äkta system (GE Healthcare).
Figure 4A demonstrates the monitored fractionation of the SUMO1 size exclusion 
chromatography. On the x-axis the elution volume is plotted in sample fraction collected. On 
the y-axis the protein concentration in mAU (milli absorbance unit) is plotted measured by 
light absorbance of the aromatic amino acids tryptophan, tyrosine and phenylalanine at 
280nm. Salt concentration is detected by monitoring the conductivity of the buffer in mS/cm 
(millisiemens / cm). The curve obtained from the SUMO1 gelfiltration indicated three peaks, 
with significant absorbance above 100mAU. The fractions of these peaks were analysed by 
?????????? ????? ??? ????? fraction on a 12.5% SDS-PAGE followed by Coomassie staining as 
shown in Figure 4B. Whereas in the first peak (fraction 19 to 30) mainly bacterial proteins 
were eluted, the second peak (fractions 31 to 28) contained near homogenous recombinant 
SUMO1. SUMO1 migrates much slower as its molecular weight of 10.5kD because of the 
flexible N-terminus. The third peak (fraction 44 to 47) overlaps with the conductivity peak 
and represents the “salt peak”. The SUMO1 containing fractions 33 to 37 were pooled, 
aliquoted, shock frozen in liquid nitrogen and stored at -80°C for further analysis. 
In a subsequent SDS-PAGE shown in Figure 4C, different amounts of the pooled SUMO1 
containing fractions were analysed for purity and for its concentration by comparison to 
known concentrations of a reference protein. Estimated concentration of SUMO1 was 
2mg/ml.
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Figure 4: Purification of SUMO1
SUMO1 was IPTG induced and expressed in E. coli BL21 gold. The purification steps included enrichment on Q Sepharose 
and subsequent size exclusion chromatography on a FPLC Äkta purifier.
(A) Chromatogram of SUMO1 size exclusion chromatography on a HiLoad S200 column.
(B) ????? ????????? ??? ?????????? ???? ???????? ?-/+IPTG) SUMO1 expression and fractions collected from the HiLoad S200 
column run were separated on a 12.5% SDS-PAGE and Coomassie stained, indicated fractions were pooled, aliquoted and 
frozen to -80°C for further analysis.
(C) Concentration of SUMO1 in comparison to the reference protein ?-Lactalbumine, Coomassie staining of ?-Lactalbumine 
and SUMO1 resolved on a 12.5% SDS-PAGE is shown.
(B)
pooled fractions
(A)
(C)
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3.1.2. Purification of the recombinant E1 enzyme Aos1/Uba2
Both Aos1 and Uba2, which were cloned under the control of the T7 promoter as His tag 
fusions, were transformed into the bacterial E.coli strain BL21 gold and expression was 
induced with IPTG for 6 hours in a total of 2 litres culture each. The proteins were purified 
separately but following  the same protocol including the binding of Aos1 and Uba2 to Ni2+
beads (ProBondTM Resin, GE Healthcare), which binds His tagged proteins. Elution was done 
with a buffer containing a high concentration of imidazole, which displaces His-tagged 
proteins from the beads. In the final step, the eluted protein containing fractions were
applied to a S200 size exclusion chromatography column on a FPLC Äkta system.
Figure 5A and Figure 5C demonstrate the chromatogram of His-Aos1 and Uba2-His
separated on a size exclusion column, respectively. His-Aos1 eluted in one broad peak with a 
shoulder?? ????? ??? ????? ????? ????????? ???? resolved on a 10% SDS-PAGE followed by 
Coomassie staining as shown in Figure 5B. All fractions contained highly concentrated, nearly
homogenous His-Aos1. Fractions 7 to 17 were pooled, aliquoted, shock frozen in liquid 
nitrogen and stored at -80°C for further purification. Uba2-His eluted in a peak with several 
????????????????????????????????????????????????????????????????????????-PAGE followed by 
Coomassie staining (shown in Figure 5D). Fractions 9 to 16 contained high amounts of Uba2 
and were therefore pooled, aliquoted, shock frozen and stored at -80°C.
Figure 5E demonstrates a dilution series of pooled His-Aos1 and Uba2-His, respectively. 
Equal amounts (4mg of each) Aos1 and Uba2 were incubated for 1 hour on ice for forming 
the active heterodimeric E1 complex, which was subsequently purified by size exclusion 
chromatography. Figure 6A demonstrates the monitored fractionation of the E1 complex on 
a gelfiltration column. The peak fractions were analysed by separation on a 5-20% SDS-PAGE 
with subsequent Coomassie staining as shown in Figure 6B. Fractions containing equal
molarities of the His-Aos1/Uba2-His complex (fractions 35 to 37), were pooled, aliquoted, 
shock frozen and stored at -80°C for further analysis.
To determine the protein concentration of the purified E1 complex, comparison to a 
reference protein was performed on a 5-20% SDS-PAGE followed by Coomassie staining
(Figure 6C). Estimated concentration of the E1 enzyme was 0.5 mg/ml.
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Figure 5: Purification of His-Aos1 and Uba2-His
His-Aos1 and Uba2-His were IPTG induced and expressed in E. coli BL21 gold. The purification steps included enrichment on 
ProBondTM Resin and subsequent size exclusion chromatography on a FPLC Äkta purifier.
(A) Chromatogram of His-Aos1 on a S200 column. 
??????????????????????????uced and induced (-/+IPTG) Aos1 expression and peak fractions collected from (A). Samples were 
separated on a 10% SDS-PAGE and Coomassie stained. Indicated fractions were pooled, aliquoted and used for further E1 
purification.
(C) Chromatogram of Uba2-His on a S200 column. 
(D) as in (B) for Uba2-His.
(E) Dilution series of His-Aos1 and Uba2-His resolved on a 5-20% SDS-PAGE followed by Coomassie staining.
(A)
(C)
(B)
(D)
(E)
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Figure 6: E1 complex formation
4 mg of each His-Aos1 and Uba2-His were pooled and incubated 1 hour on ice followed by size exclusion chromatography
on a FPLC Äkta purifier.
(A) Chromatogram of the His-Aos1/Uba2-His complex separated on a HiLoad S200 column. 
??????????????????of peak fractions were separated on a 5-20% SDS-PAGE and Coomassie stained. Indicated fractions were 
pooled, aliquoted and frozen to -80°C.
(C) Concentration determination of the heterodimeric E1 enzyme in comparison to the reference proteins ovalbumine and 
phosphorylase by Coomassie staining of ovalbumine, phosphorylase and the heterodimeric E1 resolved on a 5-20% SDS-
PAGE shown.
3.1.3. Large scale purification of the recombinant E2 enzyme Ubc9
Ubc9, which was cloned under the control of the T7 promoter, was transformed into the 
bacterial E.coli strain BL21 gold and expression was induced with IPTG in a total of 12 litres
bacterial culture. The positively charged Ubc9 was bound to the strong cation exchange 
matrix SP Sepharose (GE Healthcare). The retained Ubc9 was eluted with a phosphate 
buffer, pH 6.5, containing high salt. The Ubc9 containing eluate was applied to a HiLoad S200 
size exclusion chromatography column on a FPLC  Äkta system.
Figure 7A demonstrates the monitored fractionation of the Ubc9 size exclusion 
chromatography. As described above, the x-axis represents the elution volume in sample 
fractions and the y-axis the protein concentration in mAU (milli absorbance unit) at 280nm. 
Salt concentration is indicated as conductivity in mS/cm. Ubc9 eluted in a single peak with 
high absorbance. ????? ???????????? ???? fraction were resolved on a 12.5% SDS PAGE and 
(A)
(B)
(C)
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Coomassie stained as shown in Figure 7B.  The induction and expression of Ubc9 (-/+IPTG) 
worked very well and the fractions of the peak contained high amounts of recombinant 
Ubc9. Fractions 33 to 35 with the highest amount of Ubc9 were pooled, aliquoted, shock 
frozen in liquid nitrogen and stored at -80°C for further purification.
Different amounts of the pooled Ubc9 were finally analysed for its concentration by
comparison to a reference protein with known concentration (Figure 7C). Estimated 
concentration of Ubc9 was 2mg/ml.
Figure 7: Purification of Ubc9
Ubc9 was IPTG induced and expressed in E. coli BL21 gold. The purification steps included enrichment on SP Sepharose and 
subsequent size exclusion chromatography on a FPLC Äkta purifier.
(A) Chromatogram of Ubc9 size exclusion chromatography on a HiLoad S200 column. 
??????????????????????????uced and induced (-/+IPTG) Ubc9 expression and fractions collected from the HiLoad S200 column 
run were separated on a 12.5% SDS-PAGE and Coomassie stained, indicated fractions were pooled, aliquoted and stored at
-80°C for further analysis.
(C) Concentration of Ubc9 in comparison to the reference protein Trypsine Inhibitor, Coomassie staining of Trypsine 
Inhibitor and Ubc9 resolved on a 12.5% SDS-PAGE is shown.
pooled fractions
(B)
(A)
(C)
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3.1.3.1. Enzymatic analysis of Ubc9
Ubc9 possesses catalytic activity and therefore it is essential to test the enzymatic activity of 
the newly purified protein. This was performed by comparing its enzymatic activity with a 
previously purified Ubc9 in an in vitro sumoylation reaction. E2-25K was used as substrate,
since it is efficiently modified without an E3 ligase. 
A dilution series from 7 to 0.06 µM of the “old” and the “new” purified Ubc9 was mixed each 
????? ????????-????? ???????????????????????????? ???? ?????????? ???? ?? ?????? ??? ??????
Reactions were stopped with 2x Laemmli buffer and proteins were separated on SDS-PAGE 
followed by Coomassie staining.
Figure 8: Enzymatic analysis of Ubc9 activity by in vitro sumoylation assays with E2-25K as substrate
In vitro sumoylation?? ???? SUMO1, 70nM E1, ????? E2-25K and different amounts of old Ubc9 and new Ubc9 were 
??????????????????????????????????????ion volume without and with ATP. Reaction mix was separated on 5-20% SDS-PAGE 
and Coomassie stained.
As shown in Figure 8, the newly prepared Ubc9 was as efficient in E2-25K sumoylation as an 
older Ubc9 preparation. At the highest Ubc9 concentration approximately 80% of E2-25K 
was modified after 2 hours (lane 1 and 6). Even at the lowest Ubc9 levels E2-25K 
sumoylation was detected (lane 4 and 8). This experiment confirmed that the newly purified 
Ubc9 is as active as Ubc9 from an earlier preparation and can be used for further analysis.
3.1.4. Purification of the S*Ubc9
As described above, all proteins required for the large scale purification of sumoylated Ubc9 
were newly purified including SUMO1, the SUMO E1 activating enzyme Aos1/Uba2 and the 
SUMO conjugating enzyme Ubc9. In the next steps, the large scale in vitro sumoylation 
reaction of Ubc9 was performed and S*Ubc9 was separated from its unmodified form. It is 
important to mention that both Ubc9 and its sumoylated form had to be handled in the 
same manner for maintaining comparable enzymatic activity.
3.1.4.1. In vitro sumoylation of Ubc9
Prior to the large scale in vitro Ubc9 sumoylation, small scale reactions were performed to 
identify the optimal conditions. ?????M Ubc9, ???M SUMO1, 70nM E1 and 5mM ATP were 
?????????? ??? ????? ???? ????? ?liquots were taken every hour. Consequently, these aliquots 
were resolved on 5-20% SDS-PAGE and stained with Coomassie.
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Figure 9: Small scale in vitro sumoylation of Ubc9
In vitro sumoylation: ??????????????????????????????????? ???????????????????????????????????????????????????????????
volume with 5mM ATP and MgCl2????????????????????????????????????????????separated on 5-20% SDS-PAGE and Coomassie 
stained.
In Figure 9 the modification efficiency of Ubc9 sumoylation can be followed over time. At 
time point 0 (lane 1) the starting situation is shown. Both, Ubc9 and SUMO1 migrate at a 
similar size in a 5-20% SDS PAGE and were therefore not distinguishable in a Coomassie 
stained gel. The E1 enzyme subunits His-Aos1 and Uba2-His migrate at 40kD and 90kD,
respectively. The sumoylated Ubc9 migrates at 35kDa and was detectable already after one 
hour at 37°C in the presence of ATP. At this time point approximately 30% of Ubc9 was 
modified. In a parallel reaction, di-SUMO1 and SUMO1 chains appeared. At 2 hours 
approximately 60% of Ubc9 were modified, but also the amount of SUMO1 chains increased. 
At later time points the amount of modification neither for Ubc9 nor the SUMO1 chains 
increased, most likely because of ATP breakdown. For our use, approximately 50% of 
modified Ubc9 were required since the aim was to obtain comparable amounts of 
unmodified Ubc9, too. Therefore, the ideal condition for our approach was the incubation of 
the Ubc9 sumoylation reaction for two hours. 
For the large scale preparation of sumoylated Ubc9, the reaction mix was hundredfold 
increased (??????????????????????????????????in 20 ml SAB-buffer) and incubated for 2 
hours at 37°C with ATP. The pH of the reaction mix was 8.0. The reaction is monitored in 
Figure 10 showing aliquots before and after two hours incubation time.
Figure 10: Large scale in vitro sumoylation of Ubc9 
In vitro sumoylation: ??????????????????????????????????were incubated at 37°C for 2 hours in 20ml reaction volume 
with ATP and MgCl2. ????????????????????????????? were separated on 12.5% SDS-PAGE and stained with Coomassie. Time 
point 0 and 2 h are shown.
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3.1.4.2. Separation of the modified from the unmodified Ubc9
To separate the modified from the unmodified Ubc9, the large scale reaction was stopped by 
incubation on ice. The reaction mix was diluted 1 : 2.5 with 20mM Tris.HCl (pH 8.0) to 
decrease the salt concentration from 100mM to 40mM NaCl. These conditions allow the 
sumoylated Ubc9 but not its unmodified form to bind to the positively charged ion exchange 
HiPrep Q Sepharose column. At pH 8.0 the attachment of the negatively charged SUMO 
changes the isoelectric point of the rather positively charged Ubc9. Therefore Ubc9 was 
expected to be obtained in the “flow through”, whereas free SUMO1, SUMO1 chains and the 
sumoylated Ubc9 would bind to the column.  After washing with one column volume, elution 
was performed with a salt gradient from 40 mM to 1M NaCl for 5 column volumes. Figure 
11A demonstrates the chromatogram of the HiPrep Q Sepharose run. Sample collection 
started immediately after sample injection because of the unmodified Ubc9 in the flow 
through. The chromatogram shown in Figure 11A demonstrate a flattened curve as ‘flow 
through’ followed by a high peak with three shoulders and a third separated small peak due 
to the salt gradient elution. For verification, ?????????????????every fourth fraction in the ‘flow 
through’ or every second fraction in the elution was resolved on a 12.5% SDS-PAGE and 
Coomassie stained as shown in Figure 11B. As expected, the flow through contained the 
unmodified Ubc9, whereas the large peak with the three shoulders contained S*Ubc9, 
SUMO1 and SUMO1 chains. It was not possible to separate these three fused peaks. Their
charge is quite similar at pH 8.0. The third separated smaller peak showed no protein 
content in Coomassie staining (Data not shown). Fractions 24 to 80 were pooled to obtain all 
Ubc9, whereas fractions 114 to 122 were pooled to obtain the highest amount of S*Ubc9 
with the least SUMO1 chain contamination. The pooled fractions were used for further 
purification.
RESULTS
17
Figure 11: Large scale in vitro sumoylation of Ubc9 and initial purification via anion exchange chromatography using an 
FPLC Äkta purifier system. 
(A) Chromatogram of a large scale Ubc9 in vitro sumoylation reaction separated on a HiPrep Q Sepharose column. In vitro
sumoylation reaction was performed with ??????????????????????????????????and incubated at 37°C for 2 hours in 
20ml reaction volume with ATP and MgCl2. Prior to applying to the Q Sepharose column, the reaction mix was diluted 1: 2.5 
with 20mM Tris.HCl, pH 8.0. 
??? ????? ????????? ??? ???? ?????? ?????? in vitro ????????? ?????? ?? ???? ??? ???? ???l aliquots of fractions collected in (A) were 
separated on a 12.5% SDS-PAGE and stained with Coomassie. Indicated fractions containing Ubc9 and S*Ubc9 were pooled 
and used for further purification. 
(A)
pooled Ubc9 fractions
(B)
pooled S*Ubc9 fractions
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Additional purification steps for Ubc9 and S*Ubc9 included cation exchange and size 
exclusion chromatography. The cation exchange chromatography was not only applied to 
further purify the proteins of interest, but also to concentrate them before buffer exchange 
on a size exclusion column. To increase binding of the positively charged Ubc9 to the 
negatively charged matrix of SP sepharose, the pH 8.0 of the Tris buffer was diluted 1:1 with 
75mM BisTris (pH 6.5) resulting in full recovery of Ubc9 on the column. Elution was
performed with a salt gradient (25mM to 1M NaCl) for four column volumes. The 
chromatogram of Ubc9 on the SP sepharose XL column is shown in Figure 12A. The 
corresponding fraction resolved by separation on a 12.5% SDS PAGE and Coomassie staining 
are demonstrated in Figure 12B. Ubc9 was concentrated in three fractions, which were 
applied to a preparative S200 gel filtration column, equilibrated in the physiological 
transport buffer. Figure 12C demonstrates the chromatogram of this separation. Fractions 
43 to 49 were pooled, aliquoted, shock frozen in liquid nitrogen and stored at -80°C for 
further analysis. Figure 12D shows the concentration determination of Ubc9 in comparison 
to the reference protein Trypsine Inhibitor at indicated concentration. In conclusion, the 
purified Ubc9 has approximately a concentration of 2mg/ml.
In parallel, a similar procedure was performed for the S*Ubc9. Conjugation of the negatively 
charged SUMO reduces the positive charge of Ubc9. Also the relatively high salt 
concentration required for elution of S*Ubc9 in the previous purification step would avoid 
binding to the cation exchange column. Therefore S*Ubc9 depends on prior dialysis to 
20mM BisTris (pH 6.5) to achive efficient binding to the SP sepharose XL column. Elution 
was performed with a salt gradient (25mM to 1M NaCl) for four column volumes. In this 
step, S*Ubc9 was not only concentrated but also separated from the majority of 
contaminations, like the negatively charged free SUMO1 and SUMO1 chains. The 
chromatogram of this column run is shown in Figure 13A and the analysed fractions resolved 
on a 12.5% SDS-PAGE and Coomassie stained are shown in Figure 13B. S*Ubc9 fractions still 
contained trace amounts of SUMO1 and SUMO1 chains, most likely due to non-covalent 
interactions of Ubc9 with SUMO1/SUMO1 chains. However, fraction 29 to 31 were pooled 
and applied to the preparative S200 gel filtration column equilibrated in transport buffer. 
The chromatogram of this size exclusion chromatography is shown in Figure 13C. Fractions 
38 to 45 were pooled, aliquoted, shock frozen in liquid nitrogen and stored at -80°C for 
further experiments. Figure 13D shows the concentration determination by comparison to 
Trypsine Inhibitor and also demonstrates the purity of the preparation. The final 
concentration of S*Ubc9 was approximately 0.8mg/ml.
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Figure 12: Ubc9 concentration and buffer exchange via cation exchange chromatography followed by gelfiltration
(A) Chromatogram of Ubc9 separated on a cation exchange SP sepharose XL column.
(B) ????? ?liquots of the peak fractions were separated on a 12.5% SDS-PAGE and stained with Coomassie. Indicated 
fractions were pooled for further purification.
(C) Chromatogram of Ubc9 on a S200 size exclusion chromatography column. Peak fractions 43 to 49 were pooled, 
aliquoted and frozen at -80°C for further experiments.
(D) Coomassie stain of Ubc9 and Trypsine Inhibitor, as reference protein, separated on a 12.5% SDS-PAGE for concentration 
determination. 
(A)
(C)
(B)
(D)
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Figure 13: S*Ubc9 concentration and buffer exchange via cation exchange chromatography followed by gelfiltration
(A) Chromatogram of S*Ubc9 separated on a cation exchange SP sepharose XL column.
(B) ??????liquots of the most important fractions after the SP sepharose XL run to follow the S*Ubc9 purification. Coomassie 
staining of S*Ubc9 separated on a 12.5% SDS-PAGE is shown. Indicated fractions were pooled and used for further 
purification.
(C) Chromatogram of S*Ubc9 size exclusion chromatography on a S200 column. Fractions 38 to 45 of the peak were pooled, 
aliquoted and frozen at -80°C.
(D) Concentration of S*Ubc9 in comparison to the reference protein Trypsine Inhibitor. Coomassie staining of Trypsine 
Inhibitor and S*Ubc9 separated on a 12.5% SDS-PAGE is shown.
(A)
(C)
(B)
(D)
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Figure 14 shows a side-by-side comparison of the purified Ubc9 and the S*Ubc9 in a dilution 
series to confirm comparable molarities for further analysis.
Figure 14: Side-by-side comparison of Ubc9 and S*Ubc9
Dilution series in a range from ?????(???????????????????????????) to 1.25 µM of Ubc9 and S*Ubc9 respectively ????????
sample volume separated on a 12.5% SDS PAGE followed by Coomassie staining.
3.2.Analysis of the modified and unmodified Ubc9 to identify conditions for the 
ProtoArray®
Prior to applying the newly purified enzymes in in vitro sumoylation assays on the 
ProtoArray®, the enzymes had to be tested for their enzymatic activity and subsequently for 
their activity on known SUMO substrates to find the ideal conditions for the ProtoArray®.
3.2.1. Analysis of SUMO thioester formation ability
Different enzyme purifications can vary in enzymatic activity. Therefore it is important to 
compare Ubc9 and its sumoylated form from preparations done in parallel. To finally confirm 
comparable enzymatic activities, SUMO thioester formation assays were performed. In these 
assays, the efficiency of the SUMO transfer from the E1 enzyme to the E2 enzyme is 
measured in a time or concentration dependent manner.
Figure 15 shows such a thioester assay with HA tagged SUMO1, the E1 enzyme and similar 
concentrations of Ubc9 or S*Ubc9, respectively, in a time dependent reaction from 0 to 540 
sec. Since the thioester linkage is a relatively labile bond, the reaction was performed under 
non-reducing conditions. Sample separation was done in urea buffer on a 12.5% SDS-PAGE
for stabilizing the thioester bond. Detection was done in an immunoblot with anti-Ubc9 
antibodies.
Figure 15: SUMO thioester formation activity of Ubc9 and S*Ubc9
??????-SUMO1, 140nM E1, ATP and 500nM Ubc9 or S*Ubc9 in ?????????? ?????????? ???? ?????????? ?? ???oints at 30°C. 
Reactions were stopped with urea containing sample buffer and separated on a non-reducing 12.5% SDS Page. Detection 
was with anti-Ubc9 antibodies.
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At the concentrations used, the reaction is relatively fast and already after 20 seconds 
thioester formation can be detected. After 60 seconds it appears that the majority of E2 
input is forming a thioester bond for both the Ubc9 (lane 3) and the S*Ubc9 (lane 8).  For the 
S*Ubc9 it appears that thioester formation is further increased over time (lane 9 and 10). 
Since we only obtained a decrease in the unmodified form but did not detect a further
increase for the thioester formation, we concluded that most of the S*Ubc9 is already 
loaded at 60 seconds and the increase is lost due to irregular blotting or detection. In 
summary, Ubc9 and S*Ubc9 showed comparable enzymatic activities in thioester formation.
3.2.2. Analysis of known SUMO substrates
To further analyse the activity of Ubc9 and S*Ubc9, both enzymes were tested on substrate 
modification ability. Our laboratory has found that the transcriptional regulator Sp100 is 
significantly enhanced modified in the presence of S*Ubc9 compared to Ubc9. Therefore the 
newly purified enzymes were tested in a concentration dependent manner on Sp100 
modification. As shown in Figure 16, Sp100 sumoylation was already detected with 50nM 
S*Ubc9 (lane 8) whereas five-fold higher amounts of unmodified Ubc9 were required to 
reach comparable modification levels (lane 4).
Figure 16: In vitro sumoylation assay with GST-Sp100
????????-SUMO1, 70nM E1, 200nM GST-??????????????? ?????????? ?????????????????????????? ??????? ???????? ??????????
were incubated at 30°C for 2 hours. Samples were separated on a 7% SDS Page and detection was with either anti-GST or 
anti-HA antibodies.
Daxx sumoylation was shown to depend on a functional SIM and it is assumed that the SIM 
is rather required for recruitment of the SUMO~Ubc9 thioester than for recruting the 
S*Ubc9 conjugate 29. Since Daxx sumoylation was shown to be slightly enhanced in the 
presence of high concentrations of S*Ubc9, it was also included in our analysis. Figure 17
demonstrates the Daxx in vitro sumoylation assay with different concentrations of Ubc9 and 
S*Ubc9. In our analysis we could confirm the slight enhancment of Daxx sumoylation in the 
presence of S*Ubc9.
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Figure 17: In vitro sumoylation assay with GST-Daxx
??????-SUMO1, 200nM E1, 500nM GST-Daxx, ATP and indicated concentrations of Ubc9 or S*Ubc9 ????????????????s were 
incubated at 30°C for 2 hours. Samples were separated on a 5-20% SDS Page and detection was with anti-GST antibody.
E2-25K sumoylation was shown to be unaffected by S*Ubc9 29 and was therefore included in 
our investigation. Figure 18 demonstrates the in vitro sumoylation assay with E2-25K as 
substrate. Again we were able to confirm the results obtained before. 
Figure 18: In vitro sumoylation assay with E2-25K
????????-SUMO1, 70nM E1, 200nM E2-25K, ATP and indicated concentrations of Ubc9 or S*Ubc9 ????????????????s were 
incubated at 30°C for 2 hours and subsequently separated on a 5-20% SDS Page. Staining was with anti-HA antibody.
In summary, the newly purified enzymes were catalytically active in SUMO thioester 
formation and had similar activities on substrate sumoylation as it was described before. 
Therefore the enzymes were ready to use for the ProtoArray® service. 
3.3.The ProtoArray®
The aim of this thesis was the identification of additional substrates targeted by S*Ubc9. 
Thus, a protein microarray chip, the “ProtoArray® Human Protein Microarray v5.0” from 
Invitrogen was used. In this thesis, the ProtoArray® was applied for sumoylation reactions as 
a novel approach to identify substrates for the S*Ubc9. The ProtoArray® itself was 
performed by the Invitrogen ProtoArray® service using our concept, enzymes and conditions 
for the sumoylation reaction.
3.3.1. Novel concept to identify S*Ubc9 substrates
In collaboration with Invitrogen, we combined their knowledge and experience in applying 
the array for the identification of ubiquitin E3 ligase dependent substrates with our 
experience in in vitro sumoylation assays. In addition, we decided on detection via a HA-
tagged SUMO1 instead of the biotin tagged modifier usually used by Invitrogen. We 
expected to reduce unspecific background and increase sensitivity with the HA detection 
system. Instead of performing the reaction in duplicates, we tested two different E2 
concentrations (100nM and 500nM) to include an additional evaluation level. The concept of 
the in vitro sumoylation on the ProtoArray® is outlined in Figure 19.
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Figure 19: Concept of in vitro sumoylation on the ProtoArray®
A ProtoArray® is incubated with an in vitro sumoylation reaction mix containing 4µM HA tagged SUMO1, 100nM E1 and 
either Ubc9 or S*Ubc9, each at two different concentrations, in the presence of an ATP regenerating system. Two 
additional arrays were included as control, one containing the sumoylation reaction mix without E2 enzymes the other was 
performed with only the detection reagents. Arrays were incubated for 1hour at 30°C. After washing steps to remove all 
unconjugated components, the arrays were incubated with anti-HA antibody for 1h to select on HA-SUMO1 modified 
proteins. After additional washing steps, the arrays were incubated with Alexa647 labelled goat anti-mouse antibody for 
another hour. After final washing steps, the arrays were dried and scanned. Substrates for the sumoylated Ubc9 were 
expected to show higher values with S*Ubc9 than with Ubc9 (indicated with a red arrow).
The final conditions used for the ProtoArray® included 4µM HA-SUMO1, 100nM E1, 100nM 
or 500nM Ubc9/S*Ubc9 incubated with an ATP regenerating system in our SAB buffer 
(SUMO-Assay-Buffer) buffer with 20mM HEPES, 110mM KOAc, 2mM Mg(OAc)2, 1mM 
EGTA, pH 7.3, supplemented with 1mM DTT, 1mg/ml Leupeptin/Pepstatin, 1mg/ml 
Aprotinin, 0.05% Tween, 0.2mg/ml Ovalbumine. The reaction was performed for 1 hour at 
30°C.
As controls, one array was incubated with the detection reagent alone to define the
background and one with a reaction mix lacking the E2 enzyme to detect E2 independent 
reactions.
?
?
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Assay HA-SUMO E1 Ubc9 S*Ubc9
Negative control
E1 control ???? 100 nM
Low Ubc9 ???? 100 nM 100 nM
High Ubc9 ???? 100 nM 500 nM
Low S*Ubc9 ???? 100 nM 100 nM
High S*Ubc9 ???? 100 nM 500 nM
Table 1: Summary of conditions for different ProtoArrays
Detection of HA-SUMO1 conjugated substrates was performed with mouse anti-HA 
antibodies (Covance) and Alexa 647 labelled rabbit-anti mouse secondary antibodies 
(Invitrogen). Excitation of the fluorophore was at 650nm and detection was done at 668nm 
with a GenePix® 4000B fluorescence scanner from Molecular Devices Corporation.
3.3.2. Results of the ProtoArray® and subsequent validation
Data analysis was performed by Invitrogen ProtoArray® Service using the software 
ProtoArray® Prospector. Candidates were considered as putative SUMO substrates, when 
they produced a signal that was at least two fold above background. This criterion must have 
been met in all E2 dependent reactions tested. To define putative substrates for the 
sumoylated Ubc9, it was expected that they demonstrate a concentration dependent 
increase with S*Ubc9 and show greater signal intensity with S*Ubc9 compared to the 
respective Ubc9 concentrations. 
In order to validate the ProtoArray® screen, two putative targets preferentially modified 
with S*Ubc9 and two targets not impaired by S*Ubc9 were chosen and tested in our classical 
in vitro sumoylation assay. These targets were first cloned in bacterial expression vectors, 
expressed in E. coli, purified and finally analysed in our in vitro system. The coding DNAs
(cDNA) of these substrates were either provided from other laboratories or were obtained 
from HeLa mRNA after reverse transcription. Cloning was performed by PCR (polymerase 
chain reaction) amplification with specific primers into a pGEX vector for bacterial expression 
of glutathione-S-transferase (GST) -fused proteins. ???????????????????????????????4 were 
obtained from the Melchior, Jenuwein and Palvimo laboratories, respectively. cDNA for eIF5 
was kindly provided by Helene Klug and Lisa Kirschner. All four GST-tagged proteins were 
expressed in the bacterial strains BL21 gold or Rossetta C41 and purified by affinity to 
Glutathion-Sepharose 4B. Elution was done with 20mM glutathione. The final step included 
purification via gelfiltration on a S200 column (data not shown). 
3.3.2.1. ProtoArray® substrates enhanced modified with S*Ubc9
One of the most promising substrates identified in the ProtoArray® screen was RNF4. As 
shown in Figure 20A, RNF4 demonstrated much brighter signals in the presence of S*Ubc9 
compared to Ubc9 dependent sumoylation.
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Figure 20: Sumoylation of GST-RNF4 
(A) Block 8 of two Protein Arrays (red box) incubated with either 100nM Ubc9 (left panel) or S*Ubc9 (right panel) 
dependent in vitro sumoylation reactions. Block 8 is further enlarged and dots indicating sumoylated GST-RNF4 are marked 
with a green box.
(B) In vitro sumoylation of recombinant GST-RNF4: 21.63???SUMO1, 100nM E1, 5.75 ??????-RNF4 and 500nM Ubc9 or 
??????? ??????????????????????????????????????????????tion volume with or without ATP. Samples were resolved on a 5-20% 
SDS-PAGE and detection was with anti-SUMO1 antibodies. 
(C) ??????-SUMO1, 100nM E1, 200nM GST-RNF4, ATP and different concentrations of Ubc9 or S*Ubc9 were incubated at 
????????????????????????????ction volume. Samples were resolved on a 10% SDS-PAGE and detection was with anti-GST and 
anti-HA antibodies.
Figure 20B and 20C shows the validation of the bacterially purified GST-RNF4 in in vitro
sumoylation reactions with different Ubc9/S*Ubc9 concentrations. Indeed, also the 
bacterially purified GST-RNF4 was enhanced sumoylated in the presence of S*Ubc9 and 
therefore confirms the result obtained by ‘on chip’ sumoylation. GST-RNF4 is a novel 
substrate for S*Ubc9. 
(A)
(B)
(C)
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GST-RNF4 is very efficiently sumoylated as demonstrated in a Coomassie stain of the in vitro
modified protein in Figure 21A. RNF4 sumoylation results in at least three different slower 
migrating species, which were applied to mass spectrometry analysis performed by Dr. 
Gerhard Mittler at the MPI in Freiburg. He identified lysines K108 and K121 attached to the 
C-terminus of SUMO1 (Figure 21B). In addition, peptides, in which SUMO1 is linked to 
SUMO1, were found suggesting the involvement of SUMO chain formation rather than a 
third lysine in RNF4 to be modified. 
1        MSTRNPQRKR RGGAVNSRQT QKRTRETTST PEISLEAEPI ELVETVGDEI     
51      VDLTCESLEP VVVDLTHNDS VVIVEERRRP RRNGRRLRQD HADSCVVSSD    
101    DEELSKDKDV YVTTHTPRST KDEGTTGLRP SGTVSCPICM DGYSEIVQNG    
151    RLIVSTECGH VFCSQCLRDS LKNANTCPTC RKKINHKRYH PIYI
Figure 21: RNF4 sumoylation site mapping by mass spectrometry analysis
(A) ????????????1, 5????????????????????-?????????????????????????????????????????????????????????????????????????
reaction volume with or without ATP. Samples were resolved on a 5-20% SDS-PAGE and Coomassie stained. Bands 
representing SUMO1*RNF4, Di-SUMO1*RNF4 and Tri-SUMO1*RNF4 were applied to mass spectrometry analysis. 
(B) Protein sequence of rat RNF4. Lysines indicated in yellow were mapped as sumoylation sites in RNF4. Instead of a third 
modification site SUMO*SUMO chain linkage was identified (Mass spectrometry analysis was performed by Dr. Gerhard 
Mittler at the MPI, Freiburg)
A second substrate demonstrating enhanced signals in ‘on chip’ sumoylation reactions with 
S*Ubc9 was eIF5. Figure 22A shows the signals of eIF5 obtained with 100nM Ubc9 and 
100nM S*Ubc9, respectively, on the ProtoArray®.  
(A)
(B)
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Figure 22: Sumoylation of GST-eIF5
(A) Block 32 of two Protein Arrays (red box) incubated with either 100nM Ubc9 (left panel) or S*Ubc9 (right panel) 
dependent in vitro sumoylation reactions. Block 32 is further enlarged and dots indicating sumoylated GST-eIF5 are marked 
with a green box.
(B) In vitro sumoylation of recombinant eIF5: ?????????????????????????00nM GST-?????????????????????????????????
??????? ?????????????????????????????????????????????????????????? ??? or without ATP. Samples were resolved on a 5-20% 
SDS-PAGE and detection was with anti-GST antibody.
GST-eIF5 expressed and purified from bacteria was analysed in our in vitro sumoylation 
reactions with Ubc9 and S*Ubc9. As shown in Figure 22B, GST-eIF5 is a very inefficient 
SUMO substrate and depends on high E2 concentrations to obtain modification. Here, only 
slight enhancement in sumoylation was obtained in the presence of S*Ubc9. However, the 
enhancement identified ‘on chip’ was significantly stronger. 
3.3.2.2. ProtoArray® substrates not enhanced modified by S*Ubc9
Rcc1 and HP1? were two examples of ‘on chip’ substrates not enhanced in the presence of 
S*Ubc9 (see Figure 23A and Figure 24A). Interestingly, in case of Rcc1 sumoylation was even 
weaker with S*Ubc9. To validate the ProtoArray® screen, also these substrates were 
analysed in our in vitro assay. 
(A)
(B)
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Figure 23: Sumoylation of GST-Rcc1
(A) Block 47 of two Protein Arrays (red box) incubated with either 100nM Ubc9 (left panel) or S*Ubc9 (right panel) 
dependent in vitro sumoylation reactions. Block 47 is further enlarged and dots indicating sumoylated Gst-Rcc1 are marked 
with a green box.
(B) ?????????????????????????????????-Rcc1 and ??????of either Ubc9 or S*Ubc9 were incubated at 30°C for 2 hours in 
??????????ion volume with or without ATP. Samples were resolved on a 5-20% SDS-PAGE and detection was with anti-GST
antibody. 
Figure 23B shows the in vitro sumoylation reaction with bacterially expressed GST-Rcc1 as 
substrate. Modification was only detected at high enzyme concentrations, but the signal 
obtained for S*Ubc9 was slightly reduced and therefore consistent with the ‘on chip’ 
analysis.
(A)
(B)
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Figure 24: Sumoylation of GST-HP1?
(A) Block 10 of two Protein Arrays (red box) incubated with either 100nM Ubc9 (left panel) or S*Ubc9 (right panel) 
dependent in vitro sumoylation reactions. Block 10 is further enlarged and dots indicating sumoylated GST-HP1? are 
marked with a green box.
(B) 17.3???????1, 500nM E1, 950nM GST-HP1? and ??????of either Ubc9 or S*Ubc9 were incubated at 30°C for 2 hours 
?????????????????????????????or without ATP. Samples were resolved on a 5-20% SDS-PAGE and detection was with anti-GST
antibody.
In vitro sumoylation of the bacterially expressed GST-????? ??? ????? in Figure 24B. Again 
high concentrations of modifying enzymes were needed to detect sumoylation. The slight 
increase in sumoylation in the presence of S*Ubc9 is most likley due to differences in loading 
than enhancement of S*Ubc9. 
In summary, four substrates identified in the ProtoArray® were analysed by bacterial 
expression and purification and subsequent tesing for in vitro sumoylation with Ubc9 and 
S*Ubc9. We identified one novel substrate to be enhanced modified in the presence of 
S*Ubc9 and could verify sumoylation of three novel SUMO substrates. The modification 
efficiency of these substrates was not as efficient as assumed from the obtained `on chip´
signal.
(A)
(B)
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4. DISCUSSION
Our laboratory has recently demonstrated a novel mechanism of how sumoylation of the 
SUMO E2 conjugating enzyme Ubc9 contributes to target discrimination. Whereas 
sumoylated Ubc9 does not interfere with the sumoylation of most substrates, it impairs 
modification of RanGAP1 and significantly enhances modification of the transcriptional 
regulator Sp100 via a functional SIM motif 29. The goal of this thesis was the identification of 
additional substrates targeted by S*Ubc9 to gain insights in its target range and to learn 
thereby about its biological function. In this thesis, a novel approach for SUMO substrate 
identification was established. In vitro sumoylation reactions with Ubc9 and S*Ubc9 were 
performed on protein microarray chips purchasable from Invitrogen. Such microarrays 
contain over 9000 human proteins expressed and purified as GST-tagged proteins in insect 
cells. To perform such a screen, all proteins required for in vitro sumoylation reactions were 
expressed and purified from E.coli. This included untagged and HA-tagged SUMO1, the 
heterodimeric E1 activating enzyme Aos1/Uba2 and Ubc9. To obtain S*Ubc9, Ubc9 was in 
vitro sumoylated and separated from the unmodified form by applying different biochemical 
purification steps. Ubc9 and S*Ubc9 from the same preparation were used for further 
analysis. Before realisation on chips, all enzymes had to be tested in thioester formation 
assays for their enzymatic activities and in in vitro sumoylation assays for their ability to 
modify known substrates. The protein array screen was performed by the Invitrogen 
ProtoArray® Service and data was analysed with the ProtoArray® Prospector software. 
Candidates showing signals at least two fold above background were considered as putative 
SUMO substrates. This criterion must have been met in all E2 dependent reactions. To define 
putative substrates for the S*Ubc9, it was required that they demonstrate signals with 
higher intensity for S*Ubc9 compared to Ubc9. 
To validate the results from the ProtoArray® screen, four substrates have been chosen - two 
preferentially modified with S*Ubc9 and two preferentially modified with Ubc9. These 
substrates needed to be cloned in bacterial expression vectors, expressed in E. coli and 
purified by affinity and size exclusion chromatography. Subsequently, the substrates were 
tested in our classical in vitro modification assays, separated on SDS-PAGE and analysed by 
immunoblotting. 
The substrates selected for S*Ubc9 were the RING finger ubiquitin E3 ligase RNF4 and the 
eukaryotic translation initiation factor eIF5. 
RNF4 (also known as SNURF) is ubiquitously expressed in humans and its deregulation has 
been implicated in several human diseases including cancer 57, 58. It acts as co-activator for 
steroid receptors and other transcription factors like Sp1 59, 60. RNF4 possesses E3 ubiquitin 
ligase activity, which is dependent on its RING finger 61, 62. Intriguingly, one of its substrates 
is the PML (promyelocytic leukemia protein) modified with SUMO2 chains upon arsenic 
treatment, which results in ubiquitin-mediated degradation. Thus, RNF4 is proposed to be an 
E3 ligase specific for polysumoylated proteins 63, 64. For recognition of poly-SUMO chains, 
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four functional SIMs in RNF4 were identified 63. The presence of SIMs in RNF4 strongly 
supports our finding of RNF4 as a novel substrate for the S*Ubc9. S*Ubc9 was shown to 
enhance the affinity for selected SIM containing SUMO substrates 29. Therefore, we have 
chosen RNF4 to test it in our classical in vitro sumoylation reaction. We obtained GST-RNF4 
cloned in a vector for bacterial expression from the Palvimo laboratory and subsequently 
purified it from E.coli. Indeed, GST-RNF4 sumoylation was significantly enhanced in the 
presence of S*Ubc9 in our in vitro reactions. Hence, RNF4 represents a novel substrate for 
the S*Ubc9. This finding raises several challenging questions, like where and when in the cell 
RNF4 gets sumoylated in a S*Ubc9 dependent manner, which SIM is responsible for efficient 
sumoylation and what are the consequences on its function as ubiquitin E3 ligase. 
The second substrate selected for the S*Ubc9 was the eukaryotic translation initiation factor 
5 (eIF5). Mammalian eIF5 is a monomeric 49 kDa protein, which interacts with the ribosomal 
40S initiation complex at the mRNA start codon and promotes the hydrolysis of bound GTP. 
This leads to the release of initiation factors and allows joining of the 60S ribosomal subunit
to form the active 80S initiation complex 65. eIF5 has been shown to get phosphorylated by 
the Caseine Kinase 2 (CK2). Mutants lacking this phosphorylation site attenuate cell cycle 
progression and proliferation 66. Our ProtoArray® screen has discovered eIF5 as a novel 
SUMO substrate and it appears to be enhanced sumoylated by S*Ubc9. To verify this result, 
eIF5 was reverse transcribed from HeLa cell mRNA, amplified by PCR and cloned into a 
bacterial pGEX expression vector. GST-eIF5 was expressed and purified from E. coli and 
tested in our in vitro sumoylation assay. Sumoylation of eIF5 could be verified. However, the 
modification efficiency of eIF5 was very low and dependent on high enzyme concentrations. 
S*Ubc9 only slightly enhanced sumoylation of GST-eIF5. One difference between the assay 
on the ProtoArray® and our in vitro system is that proteins on the array are purified from
insect cells, which can positively influence protein folding.  Interestingly, eIF5 has a putative 
SIM in close proximity to two CK2 phosphorylation sites. A recent study has shown that 
phosphorylation next to selected SIMs enhance SUMO binding 28. One intriguing possibility is 
that phosphorylation is obtained by purification from insect cells, but is lacking by 
purification from bacteria, thus leading to different modification efficiencies. In the future, it 
will be important to compare the different eIF5 purifications side by side or in vitro
phosphorylate eIF5 prior to in vitro sumoylation. If phosphorylated eIF5 stimulates S*Ubc9 
dependent sumoylation, it will be exciting to investigate the resulting biological 
consequences. Both phosphorylation sites and the putative SIM are located in the glutamic 
acid-rich C-terminal region of eIF5, which is essential for the biological function of eIF5.
The second class of identified substrates analysed in this study were proteins not enhanced 
in modification with S*Ubc9. In this case, we selected to analyse HP1? and Rcc1. Rcc1 
(regulator of chromosome condensation), located in the nucleoplasm, is the guanine
nucleotide exchange factor for the Ras related GTPase Ran and plays an essential role in 
nucleo-cytoplasmic transport and in cell cycle regulation 67. HP1? (Heterochromatin protein 
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1 homolog alpha, also referred as Chromobox protein homolog 5) plays an essential role in 
heterochromatin formation by recognizing and binding to histone H3 tails methylated at 
lysine K9 68. HP1? also interacts with lamin B receptor (LBR), which contributes to the 
association of the heterochromatin with the inner nuclear membrane 69.
We obtained bacterial expression vectors for both GST-Rcc1 and GST-HP1?? from the 
Melchior and Jenuwein laboratories, respectively. Both proteins were purified after 
expression in E. coli and tested in our standard sumoylation assays. Indeed, both proteins 
were weakly sumoylated at high E2 concentration levels. These results suggest that either 
the ProtoArray® screen is more sensitive compared to our analysis and/or the difference in 
signal efficiency is due to expression in insect cells as suggested for eIF5. 
In summary, this study established a novel approach for the identification of SUMO 
substrates. Initial analysis of four substrates validates their modification in classical in vitro
sumoylation assays. Moreover, one substrate - RNF4 - was found to be significantly 
enhanced with S*Ubc9. 
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5. EXPERIMENTAL PROCEDURES
5.1.Plasmids, antibodies and bacterial strains
5.1.1. Plasmids
Protein Plasmid Selection/Marker Source
SUMO1?C4 pET11a Amp Pichler et al. 2002
HA-????????? pET23a Amp Melchior Lab
Ubc9 pET23a Amp Pichler et al. 2002
His-Aos1 pET28a Kan Pichler et al. 2002
Uba2-His pET28a Kan Melchior Lab
GST-Sp100 pGEX Amp Pichler et al. 2002
E2-25K pGEX4T Amp Pichler et al. 2005
GST-Daxx (residue 572-740) pGEX4T Amp Pichler et al. 2008
GST-RNF4 pGEX5X Amp Palvimo Lab
GST-RCC1 pGEX Amp Melchior Lab
GST-???? pGEX6P1 Amp Jenuwein Lab
GST-eIF5 pGEX6P1 Amp outlined in 5.4.7.
5.1.2. Antibodies
Antibody Source
mouse ?-SUMO1 Melchior Lab
rabbit ?-GST Melchior Lab
g?????-Ubc9 Pichler et al. 2002
monoclonal mouse ?-HA.11 Covance
HRP-coupled ?-mouse, ?-goat 
and ?-rabbit antibodies
Jackson Laboratories
????????? ????????? ?-mouse 
antibody
Invitrogen
5.1.3. Competent bacterial strains
????: E.coli F- endA1 glnV44 thi-?? ?????? ?????? ??????? ????? ????? ????lacZ????? ??lacZYA-
argF)U169, hsdR17(rK- mK+????–
BL21 gold: E. coli F- ompT gal dcm lon hsdSB(rB- mB-?????????????????R)
Rosetta C41: E.coli F- ompT hsdSB(RB- mB-?????????????????????? ??????-T7 gene 1 ind1 sam7 nin5]) 
pLysSRARE (CamR)
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5.2.Molecular cloning methods
5.2.1. Isolation of plasmid DNA from E.coli
Plasmid DNA was isolated from E.coli either using the QIAprep Spin Miniprep Kit or 
according to the protocol of a MiniPrep outlined below:
MiniPrep: Colonies were inoculated in 5ml LB/Amp and incubated o/n at 37°C. 2ml of the 
o/n culture were centrifuged for 5min at 5000rpm, 4°C, and the pellet was resuspended in 
??????????????????????????????????????????????????????????????????????????????????? ???
??????????? ??? ????? ????? ?????? ??????? ??? ??????? ?????? ??? ????? ????? ??????? ??????????
??????????????????????????? ???????????????????????????????????????????????????????????????
KCH3COO, pH 5.5) were added, mixed by vortexing and then incubated for 5min on ice. The 
mix was centrifuged for 10min at 13000rpm. After transfer of the supernatant to a new vial, 
420 µl isopropanol were added, mixed and incubated 10min at RT followed by centrifugation 
f????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????2O and storage at -20°C.
DNA concentration was measured by using the NanoDrop ND-1000 spectrophotometer from 
ThermoScientific or another photometer.  
5.2.2. Restriction digestions
Digestion of the PCR product and plasmid DNA with restriction enzymes: 
Reaction mix:
- 20µl PCR product or 10 µl plasmid DNA
- 5µl Buffer (1-4) from New England BioLabs
- 5µl 10x BSA from New England BioLabs
- 5µl 10x RNAse A
- 1.5µl restriction enzyme 1 from New England BioLabs
- 1.5µl restriction enzyme 2 from New England BioLabs
- 12µl or 22 µl ddH2O respectively
50µl total volume
All components were added to the reaction mix as indicated. The reaction mix was 
incubated for 2h at the recommended temperature. The reaction mix was then analysed by 
resolving on a 0.8% agarose gel and DNA fragments were excised from the gel. Elution of the 
fragments was done with QIAquick gel extraction kit.
5.2.3. Ligation of DNA fragments
10µl of the digested PCR product was mixed with 2µl digested plasmid DNA, 2µl T4 DNA 
Ligase Buffer (from New England BioLabs) and 1µl T4 DNA Ligase (400000U/ml, from New 
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England BioLabs), filled up to 20µl and incubated for 2h at RT. Ligation mix was added to 
100µ????????????????????????????transformation was done as described below.
5.2.4. Sequencing
DNA sequencing reactions were carried out by VBC Biotech Sequencing, Vienna, or by the 
Sequencing Facility of the Max-Planck Institute, Freiburg. 
Sequencing PCR mix:
- 300ng template DNA
- 2.4µl 5x ABI sequencing buffer
- 2pmol standard primer for pGEX
- 0.5µl Big Dye v1.1 mix
- filled  up with ddH2O
12µl total volume
Sequencing PCR program:
initial denaturation 94°C 5min
denaturation 94°C 10sec
annealing 50°C 5sec 30x
elongation 60°C 4min
storage 4°C forever
After the sequencing PCR was finished, 12µl ddH2O were added and free nucleotides were 
removed by a gel filtration on Sephadex G-50 Superfine from GE Healthcare. Capillary 
electrophoresis and subsequent data analysis was done by the Sequencing Facility at the 
Max-Planck Institute Freiburg.
5.2.5. mRNA isolation from HeLa cells 
done by Helene Klug and Lisa Kirschner
Materials:
− 6 Plates (10cm2) of Hela cells, 100% confluent
− 1x PBS: 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.76mM KH2PO4, pH adjusted to 
7.4
− TRIzol reagent
− Chloroform
− Isopropanol and 70% EtOH
− ddH2O
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6 Plates (10cm2) of Hela Cells, which were 100% confluent, were washed once with PBS. 1 ml 
of TRIzol reagent was added on each plate, the cells were resuspended and transferred to a 
fresh Eppendorf tube. 200µl of chloroform were added, mixed for several times and then 
incubated for 2 minutes, followed by centrifugation in an Eppendorf table top centrifuge for 
10min, at 4°C and 13200rpm. The upper phase was carefully transferred to a new Eppendorf 
tube. After addition of 500µl of isopropanol, the mix was incubated for 2min and 
subsequently centrifuged for another 10min at 4°C and 13200rpm. The isopropanol was 
discarded and the RNA pellet was washed once with 70%EtOH. Then the EtOH was removed 
completely and the pellet was air dried for about 10min. The RNA was resuspended in 20µl 
of ddH2O and denatured at 75°C for 10min. Then the samples were always kept on ice.
RNA concentration was measured by using the NanoDrop ND-1000 spectrophotometer from 
ThermoScientific or another photometer at OD 260. Measured RNA concentration was
~1250ng/µl
5.2.6. cDNA synthesis
done by Helene Klug and Lisa Kirschner
Materials:
− 5µg total RNA from Hela cells
− RevertAidTM First Strand cDNA Synthesis Kit 
− 10pmol/µl reverse primer 
− 10pmol/µl forward primer
− DEPC treated water
− Phusion polymerase from Finnzymes
− 5x Phusionbuffer HF from Finnzymes
− 100mM dNTPs
5µg total RNA from Hela cells + 20pmol reverse primer were mixed with DEPC-treated water 
to a total volume of 12µl and incubated for 5min at 70°C. Then the reaction mix was chilled 
on ice and 4µl 5x reaction buffer, 1µl RiboLockTM ribonuclease inhibitor (20U/µl) and 2µl 
10mM dNTP mix were added. The reaction mix was then incubated at 37°C for 5min. After 
addition of 1µl RevertAidTM M-MuLV reverse transcriptase (200U/µl), the mixture was 
incubated at 42°C for 1h. The reaction was stopped by heating at 70°C for 10min and 
subsequently diluted 1:10 with DEPC treated water.
PCR reaction with Phusion polymerase from Finnzymes:
Reaction mix:
- 2µl 5x Phusionbuffer HF 
- 0.2µl 100mM dNTPs
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- 0.5µl 10pmol/µl forward primer
- 0.5µl 10pmol/µl reverse primer
- 5µl cDNA synthesised with RevertAid Kit
- 0.1µl Phusion polymerase
- 1.7µl ddH2O
total volume of 20µl
PCR program:
initial denaturation 98°C 30sec
denaturation 98°C 10sec
annealing 65°C 30sec 35x
elongation 72°C 3min
storage 4°C forever
The PCR-products were analysed on a 1.2% agarose gel and PCR products with the expected 
size were used for cloning.
5.2.7. Cloning of eIF5 into pGEX6P1
eIF5 was amplified with eIF5 forward primer (5’AAA CGC GGA TCC GCG ATG TCT GTC AAT 
GTC AAC CGC) and eIF5 reverse primer (5’ AAA CCG CTC GAG CGG TTA AAT GGC ATC AAT 
ATC GAT GTC 3’) from cDNA as described previously. The eluted PCR product (QIAquick gel 
extraction kit) was cloned into pGEX6P1 with BamHI and XhoI (New England Biolabs)
restriction enzymes and verified by mini prep analysis and sequencing.
5.3.Biochemical methods
5.3.1. SDS polyacrylamid gel electrophoresis (PAGE)
Materials:
− ddH2O
− 2M Tris.HCl pH 8.8
− 30% Acrylamid : Bisacrylamid (30 : 0.8) Rotiphorese® from Carl Roth
− 20% SDS
− 10% APS
− TEMED
− 0.5M Tris.HCl pH 6.8
− 1x western blot running buffer: 25mM Tris, 0.19M Glycine and 0.05% SDS
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− 2x Laemmli sample buffer: 50mM Tris pH 6.8, 2% SDS, 0.1% Bromphenole Blue, 10% 
glycerin and 100mM DTT
− Protein markers: PageRulerTM prestained protein ladder and PageRulerTM unstained 
protein ladder from Fermentas Life Science
Gel recipes (for 10 gels):
SDS running gel:
5% 7% 10% 12.5% 20%
ddH2O 42.9ml 38.35ml 31.3ml 25.5ml 7.9ml
2M Tris.HCl pH 8.8 14ml
30% Acrylamid : Bisacrylamid 11.7ml 16.3ml 23.33ml 29.2ml 46.7ml
20% SDS ?????
+ 10% APS ?????
+ TEMED ????
SDS stacking gel:
2x
ddH2O 45.4ml
0.5M Tris.HCl pH 6.8 6ml
30% Acrylamid : Bisacrylamid 8ml
20% SDS ?????
+ 10% APS ?????
+ TEMED ????
SDS-PAGE: run for 1.2 – 1.5h at 25mA/ gel. 
5.3.2. Coomassie staining
− Fixing solution: 40% ethanol, 10% acetic acid
− Coomassie dye solution: 0.08 % Coomassie Brilliant Blue G250, 1.6% ortho-
phosphoric acid, 8% ammonium sulfate, 20% methanol
− Destaining solution: 1% acetic acid
Gels were fixed for 1h in the fixing solution and subsequently washed in ddH2O twice for at 
least 10 min. Then the gels were transferred into the Coomassie dye solution and stained 
o/n. Destaining was done with the destaining solution for at least one day.
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5.3.3. Semi-dry immunoblotting
Materials:
− 1x transfer buffer: 25mM Tris, 0.193M glycine, 20% methanol, 0.36 % SDS
− Whatman® gel blotting paper
− Whatman® Protran® nitrocellulose membrane
− Ponceau solution: 0.5% Ponceau S in 1% acetic acid
− PBS+0.2%Tween20: 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.76mM KH2PO4, pH 
adjusted to 7.4 + 0.2% Tween20
− 5% skimmed milk in PBS+0.2%Tween20
− Primary antibody diluted in 5% skimmed milk in PBS+0.2%Tween20
− Secondary antibody diluted 1:10000 in 5% skimmed milk in PBS+0.2%Tween20
− SuperSignal® West Pico Chemiluminescent Substrate detection reagent from Thermo 
Scientific
− Amersham HyperfilmTM ECL from GE Healthcare
Proteins were transferred onto a nitrocellulose membrane via semi-dry blotting with 0.1 A / 
gel for 1h. Afterwards, the transfer was checked by Ponceau staining and the membrane was 
washed with PBS+0.2% Tween20.
The membrane was subsequently incubated in 5% skimmed milk in PBS+0.2%Tween20 for 
1h at RT or o/n at 4°C.
Proteins were detected by incubating in primary antibody solution for 2 hours followed by 
three washes with PBS+0.2% Tween20 for 5 min and subsequent incubation with secondary 
antibody solution for 1 hour. After three washes with PBS+0-2% Tween20 for 10 minutes 
each, signals were detected with SuperSignal® West Pico Chemiluminescent Substrate 
(Thermo Scientific).
5.3.4. Expression and purification of recombinant proteins
5.3.4.1. Medium and antibiotics
LB medium (5l): 50g tryptone, 25g yeast extract, 25g NaCl, pH adjusted to 7.0
Ampicilin (Amp): 100mg/ml in H2O, stored at -20°C (1000x stock)
Kanamycin (Kan): 60mg/ml in H2O, stored at -20°C (1000x stock)
Chloramphenicol (Cam): 34mg/ml in ethanol, stored at -20°C (1000x stock)
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5.3.4.2. Transformation of plasmid DNA into competent E.coli
200ng plasmid DNA was added to ?????? ??????????E.coli and the mix was incubated for 
20min on ice. A heat shock was done for 1.5 min at 42°C followed by 5 min incubation on ice. 
1ml LB was added and E.colis were recovered for 1h at 37°C.
5.3.4.3. Expression and purification of Aos1/Uba2
Materials:
− Competent E.coli BL21 gold
− Plasmid: His-Aos1 in pET 28a, Uba2-His in pET28
− LB/Kan
− 1M IPTG
− Ni-lysis buffer: 50mM NaH2PO4, 300mM NaCl, 10mM Imidazol + 0.1mM PMSF, 1mM 
?-??????????????????????????????????????????????????????????????
− 100mM Lysozyme
− ProBondTM resin from Invitrogen (Ni-Beads)
− Ni-wash buffer: 50mM NaH2PO4, 300mM NaCl, 20mM Imidazol + ???? ?-
??????????????????????????????????????????????????????????????
− Ni-elution buffer: 50mM NaH2PO4, 300mM NaCl, 250mM I???????? ?? ???? ?-
??????????????????????????????????????????????????????????????
− Transport buffer: 20mM HEPES, 110mM KOAc, 2mM Mg(Oac)2, 1mM EGTA, titrated 
with KOH to pH 7.0 ???????????????????????????????????????????????????????
− Puck buffer: 20mM Tris (pH 8.0), ???????????????????????????????????????????????
Leupeptin/Pepstatin
− Äkta S200 10/300 GL preparative gelfiltration column 
− Äkta HiLoad 26/60 S200 prep grad preparative gelfiltration column and 5-20% PAA 
gels
Expression and Purification:
E.coli BL21 gold cells were transformed with either His-Aos1 in pET28a or Uba2-His in pET28.
A 5 ml pre-culture was grown at 37°C for several hours and diluted to 40ml LB/Kan. This 
culture was grown over night at 37°C. 
The following day, the overnight culture was diluted 1:50 in 2l LB/Kan and grown to OD600 = 
0.5-0.6 at 37°C. Expression was induced with 1 mM IPTG (1ml/L culture of a 1M stock) and 
the culture was grown for 6h at 25°C.
Bacteria were harvested by centrifugation at 4000rpm for 15min at 4°C. The pellet was 
resuspended in 40ml (20ml/L) icecold Ni-lysis buffer and frozen in liquid nitrogen followed 
by storage at -80°C.
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To purify the protein, the pellet was thawed and cells were lysed by addition of 1 mM 
lysozyme and incubation on ice for 1 hour. After 1h ultracentrifugation at 55000rpm (140000 
x g) at 4°C, the cleared lysate was applied on 5ml Ni-beads (2.5ml/l culture), equilibrated 
with Ni-lysis buffer. The mix was incubated for 1h at 4°C while rotating. Beads were 
harvested by centrifugation at 1000 rpm for 5 min at 4°C and transferred into a column. 
Beads were washed several times with Ni-wash buffer. Proteins were eluted with Ni-elution
buffer and 10x 0.5ml fractions were collected. Fractions were tested for protein by spotting 
???? ??? ????? ????????? ?? a nitrocellulose membrane and staining the spots with Ponceau. 
Protein-containing fractions were pooled and concentrated to 1ml by using a concentrator 
(Vivaspin 2). The sample was ultracentrifuged for 10min at 55000rpm and subsequently 
purified using an Äkta S200 10/300 GL column, equilibrated with transport buffer. 0.5ml 
fractions were collected and analysed via SDS-PAGE according to the chromatogram. Best 
fractions of either Aos1 or Uba2 were pooled. Aliquots of 1ml were prepared, frozen in liquid 
nitrogen and stored at -80°C. 
The concentration of both Aos1 and Uba2 was determined by resolving serial dilutions of the 
protein of interest next to a dilution series of a reference protein of known concentration on 
a 5-20% SDS-PAGE. After staining the gel with Coomassie brilliant blue, protein 
concentration was estimated.
To reconstitute the dimeric SUMO E1, equal amounts of purified Aos1 and Uba2 (4mg each) 
were incubated on ice for 1h, followed by purification via the Äkta HiLoad 26/60 S200 
preparative gelfiltration column, equilibrated in Puck buffer. Fractions of 5ml were collected
and analysed with via SDS-PAGE. Fractions containing Aos1 and Uba2 in equal amounts were 
pooled, aliquoted, frozen in liquid nitrogen and stored at -80°C.
The concentration of the E1 enzyme was determined by resolving serial dilutions of the 
protein next to a dilution series of a reference protein of known concentration on a SDS-
PAA-gel. After staining the gel with Coomassie brilliant blue, protein concentration was 
estimated. ???? ???????????????????????????????????? ?????????????????????
5.3.4.4. Expression and purification of SUMO1 and HA-SUMO1
Materials:
− Competent E.coli BL21 gold
− Plasmid: SUMO??????????????, HA-??????????????????
− LB/Amp
− 1M IPTG
− SUMO lysis buffer: 50mM Tris-HCl (pH8.8), 25mM NaCl + 0.1mM PMSF, 1mM DTT, 
?????????????????????????????????????????????
− 100mM Lysozyme
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− Q SepharoseTM Fast Flow from GE Healthcare 
− SUMO elution buffer: 50mM Tris (pH 7.5), 500??? ????? ?? ???? ????? ???????
??????????????????????????????????????
− Puck buffer for SUMO1: 20mM Tris (pH 8.0), ?????? ????? ?? ???? ????? ???????
?????????????????????????????????atin
− Transport buffer for HA-SUMO1: 20mM HEPES, 110mM KOAc, 2mM Mg(Oac)2, 1mM 
?????? ????????? ????? ???? ??? ??? ???? ?? ???? ????? ??????? ??????????? ???????
Leupeptin/Pepstatin
− Äkta HiLoad 26/60 S200 prep grad preparative gelfiltration column for SUMO1
− Äkta S200 10/300 GL preparative gelfiltration column for HA-SUMO1
− 12.5% PAA gels
Expression and Purification:
E.coli BL21 gold cells were transformed ?????????????????????????????? or HA-?????????
in pET23a.
A 5 ml pre-culture was grown at 37°C for several hours and diluted to 40ml LB/Amp. This 
culture was grown at 37°C o/n. 
The following day, the overnight culture was diluted 1:100 in 4l LB/Amp and grown to OD600 
= 0.5-0.6 at 37°C. Expression was induced with 1 mM IPTG (1ml/L culture of a 1M stock) and 
the SUMO1 culture was grown at 37°C for 4h, whereas the HA-SUMO1 was grown o/n.
Bacteria were harvested by centrifugation at 4000rpm for 15min at 4°C. The pellet was 
resuspended in 40ml icecold SUMO lysis buffer and frozen in liquid nitrogen followed by 
storage at -80°C.
The pellet was thawed, sonicated three times for 30 sec at 75% intensity and the lysate was 
cleared by ultracentrifugation for 1 hour at 55000rpm at 4°C. 10ml Q sepharose (2.5ml/l 
culture) was transferred to a column and equilibrated with SUMO lysis buffer without PMSF. 
The supernatant after ultracentrifugation was applied to the Q sepharose. Subsequently, the 
beads were washed with SUMO lysis buffer without PMSF several times. Bound protein was
eluted with SUMO elution buffer and 20x 1ml fractions were collected. Fractions were tested 
????????????????????????????????????????????????a nitrocellulose membrane and staining the 
spots with Ponceau. Protein-containing fractions were pooled and applied to the Äkta 
HiLoad 26/60 S200 preparative gelfiltration column, equilibrated in Puck Buffer. Fractions of 
5ml were collected. 
HA-SUMO1 was applied to the Äkta S200 10/300 GL preparative gelfiltration column, 
equilibrated in transport buffer. 0.5ml fractions were collected and analysed via SDS-PAGE 
according to the chromatogram. Best fractions of SUMO1 or HA-SUMO1 were pooled. 
Aliquots were prepared, frozen in liquid nitrogen and stored at -80°C. 
The concentration of both SUMO1 and HA-SUMO1 was determined by resolving serial 
dilutions of the protein next to a dilution series of a reference protein of known 
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concentration on a SDS-PAA-gel. After staining the gel with Coomassie brilliant blue, protein 
concentration was estimated. Estimated concentra????? ??? ?????????? ??????? ?? ???? ????
Estimated concentration of HA-?????? ?????????????????????
5.3.4.5. Expression and purification of Ubc9
Materials:
− Competent E.coli BL21 gold
− Plasmid: Ubc9 in pET 23a
− LB/Amp
− 1M IPTG
− Ubc9 lysis buffer: 25mM Na-phosphate (pH 6.5), 50mM NaCl + 0.1mM PMSF, 1mM 
??????????????????????????????????????????????????
− 100mM Lysozyme
− SP SepharoseTM High Performance from GE Healthcare 
− Ubc9 elution buffer: 25mM Na-phosphate (pH 6.5), 300??????????????????????????
Aprotinin, ???????????????????????????
− Puck b??????????????????????????????????????????????????????????????????????????
Leupeptin/Pepstatin
− Äkta HiLoad 26/60 S200 prep grad preparative gelfiltration column and 12.5% PAA 
gels
Expression and Purification:
E.coli BL21 gold cells were transformed with Ubc9 in pET23a. A 5 ml pre-culture was grown
at 37°C for several hours and diluted to 40ml LB/Amp. This culture was grown at 37°C o/n. 
The following day, the overnight culture was diluted 1:100 in 4l LB/Amp and grown to OD600 
= 0.5-0.6 at 37°C. Expression was induced with 1 mM IPTG (1ml/L culture of a 1M stock) and 
the Ubc9 culture was grown at 37°C for 4h. Bacteria were harvested by centrifugation at 
4000rpm for 15min at 4°C. Pellet was resuspended in 40ml icecold Ubc9 lysis buffer and 
frozen in liquid nitrogen followed by storage at -80°C. This step was repeated twice to get 3 
pellets of Ubc9 out of 12l bacterial culture.
Pellets were thawed and ultracentrifuged for 1h at 55000rpm and 4°C. 24ml SP Sepharose
(2ml/l culture) were washed, transferred to a column and equilibrated with Ubc9 lysis buffer
without PMSF. Supernatant was applied to the SP Sepharose. Subsequently, beads were 
washed with Ubc9 lysis buffer (-PMSF) for several times. Elution was done with Ubc9 elution
buffer and 30x 1ml fractions were collected. Fractions were tested for protein by spotting 
???? ??? ????? ????????? ??? a nitrocellulose membrane and staining the spots with Ponceau. 
Protein containing eluates were pooled and applied to the Äkta HiLoad 26/60 S200 prep grad 
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preparative gelfiltration column equilibrated in Puck buffer. 5ml fractions were collected and 
analysed via SDS-PAGE according to the chromatogram. Best fractions of Ubc9 were pooled. 
Aliquots of 1ml were prepared, frozen in liquid nitrogen and stored at -80°C. 
The concentration of Ubc9 was determined by resolving serial dilutions of the protein next 
to a dilution series of a reference protein of known concentration on a SDS-PAA-gel. After 
staining the gel with Coomassie brilliant blue, protein concentration was estimated.
Estimated concentration was 2mg/ml.
5.3.4.6. Expression and purification of GST tagged proteins
Materials:
− Competent E.coli BL21 gold: used for the expression of GST-Sp100, GST-E2-25K, GST-
Daxx and GST-RNF4 (RING finger protein) ?????????????????????
− Competent E.coli Rosetta C41: for the expression of GST-Rcc1, GST-????? ????GST-
eIF5?????????????????????????
− Plasmids: GST-Sp100 in pGEX
GST-E2-25K in pGEX4T
GST-Daxx in pGEX4T
GST-RNF4 in pGEX5X
GST-Rcc1 in pGEX
GST-???????????????
GST-eIF5 in pGEX6P1
− LB/Amp or LB/Amp/Cam, 1M IPTG
− ???????????????????????????????????????????????2
− Lysis buffer: 50mM Tris-HCl (pH 8.0), 100mM NaCl + 0.??????????????????????????
??????????????????????????????????????
− 100mM Lysozyme
− Glutathione Sepharose 4B (GST-beads) from GE Healthcare
− GSH elution buffer: 50mM Tris, 20mM glutathione, reduced (pH 8.0) +1mM DTT, 
????????????????????????????????????????????
− Transport buffer: 20mM HEPES, 110mM KOAc, 2mM Mg(Oac)2, 1mM EGTA, titrated 
with KOH to pH 7.0 ???????????????????????????????????????????????????????
− Äkta S200 10/300 GL preparative gelfiltration column and 6 - 12.5% PAA gels
depending on the molecular weight of the protein
− Reference proteins: ?-Lactalbumine [10mg/ml] 14.2 kD 
Trypsine Inhibitor [10mg/ml] 20.1 kD
Ovalbumine [10mg/ml] 44.3 kD
BSA [2mg/ml] 66.0 kD
Phosphorylase [1mg/ml] 97.2 kD
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E.coli BL21 gold or E.coli Rosetta C41, respectively, were transformed with plasmid DNA as 
mentioned above. A 5 ml pre-culture was grown at 37°C for several hours and diluted to 
40ml LB/Amp or LB/Amp/Cam. This culture was grown at 37°C o/n. 
The following day, the overnight culture was diluted 1:50 in 2l LB/Amp or LB/Amp/Cam, 
respectively. ??????????????????????????????????????????????ZnCl2. The culture was grown to 
OD600 = 0.5-0.6 at 37°C. Expression was induced with 1 mM IPTG (1ml/L culture of a 1M 
stock) and the culture was grown at 16°C for 6h. Bacteria were harvested by centrifugation 
at 4000rpm for 15min at 4°C. Pellet was resuspended in 40ml icecold lysis buffer and frozen 
in liquid nitrogen followed by storage at -80°C.
To purify the protein, the pellet was thawed and cells were lysed by addition of 1 mM 
lysozyme and incubation on ice for 1 hour. After 1h ultracentrifugation at 55000rpm at 4°C, 
the cleared lysate was applied to 4ml GST-beads (1-2ml/l culture), which had been 
equilibrated with lysis buffer. Supernatant and beads were incubated for 1.5h at 4°C on 
rotation.
Subsequently, beads were washed several times with lysis buffer (-PMSF). Bound proteins 
were eluted with GSH elution buffer and 10x 0.5ml fractions were collected. Fractions were 
???????????????????????????????????????????????????????a nitrocellulose membrane and staining 
the spots with Ponceau. Protein containing eluates were pooled and applied to the Äkta 
S200 10/300 GL column equilibrated in icecold transport buffer. 0.5ml fractions were 
collected and analysed via SDS-PAGE according to the chromatogram. Best fractions were 
pooled, aliquoted, frozen in liquid nitrogen and stored at -80°C. 
The concentration was determined by resolving serial dilutions of the protein next to a 
dilution series of a reference protein of known concentration on a SDS-PAA-gel. After 
staining the gel with Coomassie brilliant blue, protein concentration was estimated.
Estimated Concentrations: GST-Sp100 2mg/ml = ?????????-Daxx 2mg/ml= 30???????-RNF4 
= 23???????-Rcc1 1.5mg/ml ????????, GST-????????????? ????????, GST-eIF5 = 0.8mg/ml 
????????.
5.3.4.7. Removing the GST tag by using TEV protease
Materials:
− Glutathione Sepharose 4B (GST-Beads) from GE Healthcare
− Transport buffer: 20mM HEPES, 110mM KOAc, 2mM Mg(Oac)2, 1mM EGTA, titrated 
with KOH to pH 7.0 + PI
− ?????????????????
− Vivaspin 20 centricon (10000 MWCO PES) from Sartorius Stedim
− Äkta S200 10/300 GL preparative gelfiltration column and 12.5% PAA gels 
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Expression and harvest of E2-25K was done as described previously. After lysis and 
ultracentrifugation, the supernatant was incubated with equilibrated GST-beads for 1.5h.
Subsequently, the beads were washed three times with transport buffer. The buffer was 
then removed and the beads were resuspended in 3ml transpor????????????????????????????
was added and the reaction mix was incubated o/n at 4°C while rotating.
The following day, the reaction mix including the beads was loaded on a small column and 
the flow through was collected. The beads were washed two times with 3ml transport buffer 
and the flow through was again collected. Then, the pooled flow through was concentrated 
with a Vivaspin 20 centricon to 1ml. After ultracentrifugation to remove precipitates, the 
sample was applied to the equilibrated Äkta S200 10/300 GL column. 0.5ml fractions were 
collected and analysed as described previously. Best fractions were pooled, aliquoted, frozen 
in liquid nitrogen and stored at -80°C. 
The concentration was determined by resolving serial dilutions of the protein next to a 
dilution series of a reference protein of known concentration on a SDS-PAA-gel. After 
staining the gel with Coomassie brilliant blue, protein concentration was estimated.
Estimated concentration of E2-???? ??????????
5.3.4.8. In vitro sumoylation of Ubc9 and separation of the modified 
from the unmodified form
Materials:
− Purified SUMO1, Ubc9 and Aos1/Uba2
− Äkta HiPrep 16/60 Q FF anion exchange column
− HiPrep buffer A: 20mM Tris pH 8.0, 40mM NaCl + PI
− HiPrep buffer B: 20mM Tris pH 8.0, 1M NaCl + PI
− 75mM BisTris pH 6.5 + PI
− 20mM BisTris pH 6.5 + PI
− Äkta HiTrap SP XL cation exchange column
− SP XL buffer A: 20mM BisTris pH 6.5, 25mM NaCl + PI
− SP XL buffer B: 20mM BisTris pH 6.5, 1M NaCl + PI
− Äkta S200 10/300 GL preparative gelfiltration column
− Transport buffer: 20mM HEPES, 110mM KOAc, 2mM Mg(Oac)2, 1mM EGTA, titrated 
with KOH to pH 7.0 + PI
− 12.5% PAA gels
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Molarities of the in vitro sumoylation reaction of Ubc9:
???????????
??????????
70nM E1
5mM ATP
5mM MgCl2
0.1mM DTT
Reaction mix of the small scale in vitro sumoylation of Ubc9 ???????:
????g Ubc9
13??g SUMO1 
???g E1 
5mM MgCl2
5mM ATP
0.1mM DTT
total volume ~ 20??l
??reaction mix was incubated for 5h at 37°C?????????????????????????????????taken 
and resolved on a 5-20% SDS-PAGE
Reaction mix of the large scale in vitro sumoylation of Ubc9 (in mg):
20mg Ubc9
13mg SUMO1 
1.5mg E1 
5mM MgCl2
5mM ATP
0.1mM DTT
total volume ~ 20ml
??????????? ??? ?????????????????????????°C, pH of the reaction was pH 8.0
The reaction mix was diluted 1: 2.5 (1+1.5 volumes) in 20mM Tris.HCl (pH8.0) + PI and 
applied to the Äkta HiPrep 16/60 Q FF column equilibrated in HiPrep buffer A. Fractions of 
1ml were collected and analysed via SDS-PAGE. Free Ubc9 did not bind to the column and
was washed out with at least 1 column volume of HiPrep buffer A. The bound proteins
(S*Ubc9, SUMO1 and E1) were eluted with a NaCl gradient over 5 column volumes with the 
final concentration of buffer B (1M NaCl). 1ml fractions were collected and analysed via a 
chromatogram and SDS-PAGE. Fractions containing the highest amounts of Ubc9 and
S*Ubc9, respectively, were pooled.
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Pooled Ubc9 was diluted 1:1 with 75mM BisTris (pH 6.5) and applied to the Äkta HiTrap SP 
XL cation exchange column by using the buffer intake tubing. The column was washed with 5 
column volumes of SP XL buffer A to wash out all unbound proteins. Ubc9 was eluted with a 
NaCl gradient over 4 column volumes with the final concentration of SP XL buffer B (1M 
NaCl). 1ml fractions were collected and analysed with a chromatogram and SDS-PAGE. 
Fractions, which contain the highest amount of Ubc9, were pooled and, in order to change 
the buffer, applied to Äkta S200 10/300 GL preparative gelfiltration column equilibrated in 
transport buffer. Fractions of 0.5 ml were collected and analysed with a chromatogram and 
subsequent SDS-PAGE. Fractions containing the highest amount of Ubc9 were pooled, 
aliquoted, frozen in liquid nitrogen and stored at -80°C.
Pooled S*Ubc9 was dialysed with 2l of 20mM BisTris (pH 6.5) for 3h and applied to the Äkta 
HiTrap SP XL cation exchange column by using the buffer intake tubing. The column was 
washed with 5 column volumes of SP XL buffer A to wash out all unbound proteins. S*Ubc9 
was eluted with a NaCl gradient over 4 column volumes with the final concentration of SP XL 
buffer B (1M NaCl) as described for the Ubc9. 1ml fractions were collected and analysed with 
a chromatogram and subsequent SDS-PAGE. Fractions, which contain the highest amount of 
S*Ubc9, were pooled and again, in order to change the buffer, applied to Äkta S200 10/300 
GL preparative gelfiltration column equilibrated in transport buffer. Fractions of 0.5ml were 
collected and analysed with a chromatogram and subsequent SDS-PAGE. Fractions, which 
contain the highest amount of S*Ubc9, were pooled, aliquoted, frozen in liquid nitrogen and 
stored at -80°C. 
The concentration was determined by resolving serial dilutions of the protein next to a 
dilution series of a reference protein of known concentration on a SDS-PAA-gel. After 
staining the gel with Coomassie brilliant blue, protein concentration was estimated.
???? ??????????????????????????? ??????????????????????????????????????????????????
5.3.5. In vitro thioester assay
Reaction mix:
Solution [Conc.] Volume Final Concentration
HA-SUMO1 ??????M] 0.88 ?? 4.4 ??
Aos1-Uba2 ???????] ?????? 140 nM
Ubc9 ???????] 0.09 ?? - 500 nM
S*Ubc9 [?????] - 0.372 ?? 500 nM
ATP [100 mM] 1 ?? ????
10x thioester buffer 
(200mM Tris pH 7.6, 
500mM NaCl, 100mM 
MgCl2)
2 ?? 20 mM Tris pH 7.6, 
50 mM NaCl, 
10 mM MgCl2
ddH20 + 1 mM AP + LP ?????
1 mM DTT 0.81 ?? 0.5???? 0.1 mM DTT
total 20 ??
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All components were added to the reaction mix and thioester formation was induced by 
adding ATP. Thioester formation was stopped by adding ??????rea buffer (50mM Tris-HCl pH 
6.8, 2% SDS, 10% glycerol and 4M urea) after incubation for 0 / 20 / 60 / 180/ 540 sec at 
30°C. Prior to loading, samples were incubated for 15 min at 30°C. Non-reducing SDS-PAGE 
was done at 15mA/gel and 4°C.
5.3.6. In vitro sumoylation assay
Reaction mix to test the enzymatic activity of Ubc9:
Solution [Conc.] Volume Final Concentration / Amount
SUMO1 ???????] 2.2 ?? 19 ?M ????????
Aos1-Uba2 ???????? ?????? 70 nM ????????
old Ubc9 ???????? ???? - X
new Ubc9 ???????? - ???? X
E2-25K ??????? ?????? ?????? ????????
ATP [100mM] ???? ????
SAB (1x transport buffer, 
2mg/ml ovalbumin, 0.05% 
Tween, 1mM LP, AP, DTT)
???????
total ????
X = 7 / 1.4 / 0.28 / 0.06 ???????old and new Ubc9
Reaction mix for Sp100 and E2-25K:
Solution [Conc.] Volume Final Concentration
HA-SUMO1 ???????? ??????? ??????
Aos1-Uba2 ???????? ?????? 70 nM
Ubc9 ???????? ???? - ???? - X
S*Ubc9 ??????? - ???? - ???? X
Sp100 ??????????? ??????? - 200 nM
E2-25K ???????? - ?????? 200 nM
ATP [100mM] ???? ????
SAB (1x transport buffer, 
2mg/ml ovalbumin, 0.05% 
Tween, 1mM LP, AP, DTT)
x
total ????
X = 1250 / 250 / 50 / 10 / 0 nM 
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Reaction mix for Daxx:
Solution [Conc.] Volume Final Concentration
HA-SUMO1 ???????? ?????? ????
Aos1-Uba2 ???????? ??????? 200 nM
Ubc9 ???????? ???? - X
S*Ubc9 ??????? - ???? X
Daxx ??????? ???????? 500 nM
ATP [100mM] ???? ????
SAB (1x transport buffer, 
2mg/ml ovalbumin, 0.05% 
Tween, 1mM LP, AP, DTT)
1????????
total ????
X = 2500 / 500 / 100 / 20 / 0 nM
Reaction mix for RNF4 + SUMO1:
Solution [Conc.] Volume Final Concentration
SUMO1 ???????? ?????? ????????
Aos1-Uba2 ???????? ??????? 100 nM
Ubc9 ???????? 0.09 ?? - 500 nM
S*Ubc9 ??????? - 0.37 ?? 500 nM
RNF4 ???????? ???? ???????
ATP [100mM] ???? ????
SAB (1x transport buffer, 
2mg/ml ovalbumin, 0.05% 
Tween, 1mM LP, AP, DTT)
10.97 ?? 10.69 ??
total ????
Reaction mix for RNF4 + HA-SUMO1:
Solution [Conc.] Volume Final Concentration
HA-SUMO1 ???????? ?????? ????
Aos1-Uba2 ???????? ??????? 100 nM
Ubc9 ???????? ???? - X
S*Ubc9 ??????? - ???? X
RNF4 ???????? ??????? 200 nM
ATP [100mM] ???? ????
SAB (1x transport buffer, 
2mg/ml ovalbumin, 0.05% 
Tween, 1mM LP, AP, DTT)
13.59 ??
total ????
X = 2500 / 500 / 100 / 20 / 0 nM
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Reaction mix for Rcc1 + SUMO1:
Solution [Conc.] Volume Final Concentration
SUMO1 ???????? ???? ???????
Aos1-Uba2 ???????? ?????? 500 nM
Ubc9 ???????? ??????? - ??????
S*Ubc9 ??????? - ??????? ??????
Rcc1 [21.4 ???? ??????? 700 nM
ATP [100mM] ???? ????
SAB (1x transport buffer, 
2mg/ml ovalbumin, 0.05% 
Tween, 1mM LP, AP, DTT)
13.69 ?? 12.29 ??
total ????
Reaction mix ?????????? SUMO1:
Solution [Conc.] Volume Final Concentration
SUMO1 ???????? ???? ???????
Aos1-Uba2 ???????? ?????? 500 nM
Ubc9 ???????? ??????? - ??????
S*Ubc9 ??????? - ??????? ??????
?????????????? ??????? 950 nM
ATP [100mM] ???? ????
SAB (1x transport buffer, 
2mg/ml ovalbumin, 0.05% 
Tween, 1mM LP, AP, DTT)
???????? ????????
total ????
Reaction mix for eIF5 + SUMO1:
Solution [Conc.] Volume Final Concentration
SUMO1 ???????? ???? ???????
Aos1-Uba2 ???????? ?????? 500 nM
Ubc9 ???????? ??????? - ??????
S*Ubc9 ??????? - ??????? ??????
eIF5 [10?????? 0.38 ?? 200 nM
ATP [100mM] ???? ????
SAB (1x transport buffer, 
2mg/ml ovalbumin, 0.05% 
Tween, 1mM LP, AP, DTT)
???????? ????????
total ????
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All components were added to the reaction mix as indicated. ATP was added last in order to 
start the sumoylation reaction. The reaction mix was incubated for 2h at 30°C and stopped 
by adding 20?l 2x Laemmli buffer and boiling for 5 min at 95°C. Samples were centrifuged 
and loaded on PAA gels. Proteins were detected either by Coomassie staining or 
immunoblotting. 
5.4.ProtoArray® assay
5.4.1. Probing the ProtoArray®
Materials:
− 6 ProtoArray® Human Protein Microarrays 5.0 from Invitrogen incubated with:
o 1x 100nM Ubc9 + reaction mix
o 1x 100nM S*Ubc9 + reaction mix
o 1x 500nM Ubc9 + reaction mix
o 1x 500nM S*Ubc9 + reaction mix
o 1x Reaction Mix without Ubc9/S*Ubc9
o 1x Detection reagent alone
− Stock concentrations:
• HA-SUMO1: 1.5mg/ml = 100 µM
• E1 enzyme: 0.5mg/ml = 4.5 µM
• Ubc9: 2 mg/ml = 111 µM
• S*Ubc9: 0.8mg/ml = 27 µM
− SAB buffer: transport buffer ( =20 mM HEPES, 110 mM KOAc, 2 mM Mg(OAc)2, 1 mM 
EGTA, ph 7.3 (KOH)) + 1mM DTT, 1mg/ml Leupeptin/Pepstatin, 1mg/ml Aprotinin, 
0.05%Tween, 0.2mg/ml ovalbumine
− ATP regenerating system from Invitrogen
− Blocking buffer from Invitrogen: 50mM HEPES pH 7.5, 200mM NaCl, 0.08% Triton X-
100, 25% glycerol, 20mM reduced glutathione, 1mM DTT, 1% BSA
− 0.5% SDS from Invitrogen
− Assay buffer from Invitrogen: 50mM Tris.HCl pH 7.5, 50mM NaCl, 5mM MgSO4, 0.1% 
Tween20, 1mM DTT, 1% BSA
− ?-HA.11 antibody from Covance in Assay Buffer (1:1500 dilution, end conc. = 3.3 –
4.6 µg/ml)
− Alexa647 ??????-mouse antibody from Invitrogen in assay buffer (1:2000 dilution, 
end conc. = 1µg/ml)
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Reaction mixes in detail:
100nM 
Ubc9
100nM 
S*Ubc9
500nM 
Ubc9
500nM 
S*Ubc9
- Ubc9/
S*Ubc9
Detection 
reagent 
alone
4µM
HA-
SUMO
4 µl 4 µl 4 µl 4 µl 4 µl -
100nM 
E1
2.22 µl 2.22 µl 2.22 µl 2.22 µl 2.22 µl -
Ubc9 0.09 µl - 0.45 µl - - -
S*Ubc9 - 0.37 µl - 1.85 µl - -
ATP 5 µl 5 µl 5 µl 5 µl 5 µl -
SAB ???????? ???????? ???????? ???????? ???????? 100 µl
100 µl 100 µl 100 µl 100 µl 100 µl 100 µl
All samples were sent to Invitrogen ProtoArray® Service at -20°C, the antibody was sent at 
4°C. Probing the ProtoArray® was done by the ProtoArray® Service of Invitrogen as described 
in the next steps.
The ProtoArray® was equilibrated for 15min at 4°C upon removal from storage at -20°C. 
Then each chip was blocked with 5ml blocking buffer for 1h at 4°C on a circular shaker at 
50rpm. After blocking the chips were washed with 5ml assay buffer for 3min.
For probing the ProtoArray®, ???????reaction mix were dropped on the respective array and 
incubated for 1h at 30°C in a humidified chamber. 
The ProtoArray® was then washed 1x with 5ml assay buffer, 3x with 5ml 0.5% SDS for 5min 
and 2x with 5ml assay buffer.
The ProtoArray® ???? ?????????? ????? ?-HA.11 antibody from Covance (stock conc. = 5-
7mg/ml, dilution 1:1500, end conc. = 3.3 – 4.6 µg/ml) for 1h at 4°C followed by washing 5x 
with 5ml assay buffer for 5min.
Subsequently, the ProtoArray® was incubated with Alexa647 goat anti-mouse antibody 
(stock conc. = 2mg/ml, dilution 1:2000, end conc. = 1µg/ml) for 1h at 4°C followed again by 
washing 5x with 5ml assay buffer for 5min.
The ProtoArray® was dried by centrifugation at 200 x g for 1min at RT and detection was 
done by scanning the chip at 668nm with the fluorescence scanner GenePix® 4000B from 
Molecular Devices Corporation.
5.4.2. Data analysis
Data analysis was done with the software ProtoArray® Prospector from Invitrogen.
Additionally, candidates were also identified as SUMO substrates, if 50% of the pixels 
produced a signal greater than two standard deviations (??= 755,7) above the background. 
Candidates must meet this criterion on all of the assayed slides incubated with 100 or 
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500nM E2 concentration. Once the SUMO substrate list was generated, the spots were 
calculated for their signal intensity. 
Calculation was done as 
?????? ????????? = (???? ?????? ?? ??? ?????????? ???? ? ??????????)???? ??????? ????????????? ?? ??? ????
Signal intensity with S*Ubc9 was then correlated to the signal intensity of the corresponding 
spots on an array incubated with the same concentration of Ubc9. Calculation was done as
??????????? ????? = ?????? ????????? ? ? ???9?????? ????????? ???9
Thus, two values are generated by correlating 100nM S*Ubc9 with 100nM Ubc9 and 500nM 
S*Ubc9 with 500nM Ubc9. All candidates with a correlation value ??1 at both concentrations 
(21 proteins) were chosen as ‘high-confidence' substrates, which were preferentially 
targeted by S*Ubc9 over Ubc9. Conclusions could be drawn from the difference in signal 
intensity to modification efficiency with the requirement that results were located in the 
linear range (1510 – 65500). 
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6. ABBREVIATIONS
ADP adenosine di-phosphate
Aos activation of Smt3p
AP aprotinin
ATP adenosine tri-phosphate
BLM Bloom syndrome protein
CK2 caseine kinase 2
Daxx death domain-associated protein 6
DTT dithiothreitol
eIF eukaryotic initiation translation factor 
FPLC fast protein liquid chromatography
GSNO S-nitrosoglutathione
GST glutathione-S-transferase
GTP guanosine triphosphate
HA hemagglutinin
HIPK2 homeodomain-interacting protein kinase 2
HIS poly-histidine
HP1? heterochromatin protein 1 alpha
IB immunoblot
IPTG Isopropyl-?-D-thiogalactopyranosid
LP leupeptin / pepstatin
NDSM negative charged dependent SUMO motif
o/n over night
PAA polyacrylamide
PCR polymerase chain reaction
PDSM phosphorylation dependent SUMO motif
PI protease inhibitors
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PIAS protein inhibitor of activated STAT
PML promyelocytic leukemia 
RanGAP Ran GTP activating protein
RCC regulator of chromosome condensation
RING really interesting new gene
RNF4 RING finger protein 4
S* sumoylated
SBM SUMO binding motif
SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis
SIM SUMO interaction motif
SUMO small ubiquitin-related modifier
TDG thymine DNA glycosylase
Uba Ubiquitin activating
Ubc Ubiquitin conjugating
Ulp Ubiquitin-like proteases
USP25 Ubiquitin carboxyl-terminal hydrolase
* isopeptide bond
~ thioester bond
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